A summary of some notable key multiple myeloma research from October-November 2026
Scope and Methodology
This week’s blog summarizes key multiple myeloma research published in several peer-reviewed publications and medical journals from October-November 2026. Content was developed by the International Myeloma Foundation medical editorial team using various medical abstracts on new guidelines, recommendations, clinical updates, reviews, letters to the editor, correspondence, and the latest results of ongoing clinical trials. It is intended for patients, care partners, and oncology professionals. This blog article was medically reviewed by Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO, on November 18, 2026. The blog reflects medical guidance available at the time of review and is not routinely updated.
Guidelines & Recommendations
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of multiple myeloma, version 2.0. — Journal for ImmunoTherapy of Cancer (November 2026)
What is the purpose of this clinical practice guideline (CPG)?
To provide evidence-based and expert consensus-based recommendations for the use of approved immunotherapies in patients with multiple myeloma (MM), including newly diagnosed and relapsed/refractory (RRMM) disease. It aims to guide healthcare professionals in treatment selection, sequencing, administration, toxicity management, and patient care to support improved clinical outcomes.
Summary
The Society for Immunotherapy of Cancer (SITC) developed a multidisciplinary, evidence-based clinical practice guideline addressing the use of chimeric antigen receptor (CAR) T-cell therapies, T-cell engager (TCE) bispecific antibodies, antibody-drug conjugates (ADCs), and monoclonal antibody (mAb)-based combinations targeting B-cell maturation antigen (BCMA), G protein-coupled receptor class C group 5 member D (GPRC5D), and CD38 in patients with MM. Recommendations were developed through literature review, expert consensus, and a modified Delphi process, with all recommendations achieving at least 85% expert panel agreement. The guideline addresses treatment selection and sequencing, practical administration considerations, toxicity management, special patient populations, infection prevention, patient education, and quality of life (QOL).
Key points
Guideline development and methodology
• Developed by the SITC Multiple Myeloma Immunotherapy Guideline Expert Panel under the SITC Cancer Immunotherapy Guidelines Oversight Committee.
• Followed the Institute of Medicine (IOM) Standards for Developing Trustworthy Clinical Practice Guidelines.
• Recommendations were based on published literature and expert clinical experience.
• A modified Delphi process and expert consensus discussions were used to refine recommendations.
• All recommendations achieved at least 85% consensus.
• Evidence was graded using the Oxford Centre for Evidence-Based Medicine (OCEBM) Levels of Evidence (Levels 1–5).
• The guideline underwent public external review, with stakeholder comments evaluated by the Expert Panel.
• The guideline was funded solely by SITC, without commercial funding.
Treatment recommendations for NDMM
• A four-drug regimen comprising an anti-CD38-based therapy, a proteasome inhibitor (PI), and an immunomodulatory drug (IMiD) is recommended for patients with NDMM (LE: 1–2).
• For frail patients, an anti-CD38 antibody plus an IMiD may be considered (LE: 1).
• For patients presenting with severe renal impairment, a PI-based combination, with or without an anti-CD38 monoclonal antibody and/or cyclophosphamide, is recommended for initial induction (LE: 2–3).
• IMiDs may be considered after renal function improves or stabilizes (LE: 3).
Treatment Recommendations for RRMM
• CAR T-cell therapies and TCE therapies targeting BCMA or GPRC5D are important treatment options for RRMM.
• Approved CAR T-cell therapies include:
- Idecabtagene vicleucel (ide-cel)
- Ciltacabtagene autoleucel (cilta-cel)
• Approved TCE therapies include:
- Teclistamab
- Elranatamab
- Talquetamab
- Linvoseltamab
• The approved BCMA-targeting ADC is belantamab mafodotin.
• Cilta-cel or teclistamab plus daratumumab may be considered after at least one prior line of therapy (LE: 2).
• Ide-cel may be considered after at least two prior lines of therapy (LE: 2).
• The four approved TCE therapies may be considered after at least four prior lines of therapy (LE: 3).
• Belantamab mafodotin combined with bortezomib and dexamethasone may be considered after at least two prior lines, including a PI and an IMiD (LE: 2).
• Treatment selection should consider prior treatment exposure, refractoriness, patient fitness, disease characteristics, treatment accessibility, and the need for a rapid response.
• Early referral to a specialized CAR T-cell treatment center is recommended at relapse (LE: 2).
CAR T-cell and TCE treatment considerations
• Treatment sequencing should account for prior immunotherapies and potential resistance mechanisms.
• Switching to a different therapeutic target should be considered when selecting sequential immunotherapies, when possible (LE: 3).
• Immunosuppressive treatments, including bendamustine and high-dose alkylating agents, should be avoided immediately before CAR T-cell or TCE therapy (LE: 3).
• Bridging therapy (BT) may be used before CAR T-cell infusion to control disease during the manufacturing period. Its selection should consider disease burden, progression rate, treatment sensitivity, and toxicity (LE: 3).
• Pre-treatment evaluation for CAR T-cell and TCE therapy should include:
- Hepatitis B and C, HIV, and CMV screening
- Bone marrow biopsy and PET scan
- Quantitative immunoglobulin levels
- Baseline CD4 T-cell counts and immunodeficiency assessment
• Echocardiography, with or without pulmonary function testing, may also be included before CAR T-cell therapy.
• Inpatient monitoring is recommended for active cytokine release syndrome (CRS) and/or neurological toxicity. Outpatient monitoring may be considered at appropriately equipped treatment centers for selected patients (LE: 3).
Treatment considerations for special patient populations
• Extramedullary disease (EMD): CAR T-cell and TCE therapies are recommended options, although EMD has been associated with poorer progression-free survival (PFS) and overall survival (OS) following CAR T-cell therapy.
• Central nervous system (CNS) involvement: CAR T-cell therapy may be considered when clinically indicated, although efficacy and safety data remain limited (LE: 3).
• Plasma cell leukemia (PCL): CAR T-cell therapy may be considered, with disease debulking prioritized before treatment and close monitoring for adverse events (AEs) (LE: 3).
• High-risk disease: Early referral to a CAR T-cell treatment center and consideration of clinical trial enrollment are recommended.
• Early relapse: CAR T-cell therapy may be considered for patients experiencing disease progression within 12 months after autologous stem cell transplantation (ASCT) or initial PI- and IMiD-containing treatment.
• Advanced age and frailty: Advanced age alone does not exclude patients from CAR T-cell or TCE therapy. Fitness and performance status are important treatment considerations (LE: 3).
• Renal insufficiency or failure: Renal failure alone is not an absolute contraindication to CAR T-cell or TCE therapy. Fludarabine dose adjustment and nephrology consultation are recommended when appropriate, particularly for patients with a glomerular filtration rate (GFR) below 30 mL/min.
• Concurrent AL amyloidosis: Patients with adequate organ function may receive CAR T-cell or TCE therapy and should be referred to specialized treatment centers (LE: 4).
Toxicity management and infection prevention
CAR T-cell therapy
• Important toxicities include CRS, immune effector cell-associated neurotoxicity syndrome (ICANS), cytopenias, cardiac toxicities, hypogammaglobulinemia, and infections.
• Delayed neurological toxicities may include cranial nerve palsies, peripheral neuropathy, IEC-Parkinsonism, and movement and neurocognitive treatment-emergent adverse events (MNTs).
• Monitoring for delayed neurological symptoms, including handwriting changes, is recommended.
• CAR T-cell-associated cytopenias may take up to three months to recover and may require transfusions and growth factor support.
• Patients with serious, recurrent, or persistent infections should be evaluated by an infectious disease specialist.
TCE therapy
• Common toxicities include CRS, ICANS, hematological toxicities, and infections.
• CRS occurred in approximately 56.3%–80% of patients in the registrational trials of teclistamab, elranatamab, and talquetamab.
• ICANS occurred in approximately 3%–10% of patients in the registrational trials of approved TCE therapies.
• Step-up dosing, required premedications, and Risk Evaluation and Mitigation Strategies (REMS) programs should be followed.
• Tocilizumab should be available during TCE step-up dosing to manage CRS.
• G-CSF may be used to manage neutropenia.
• Pneumocystis jirovecii pneumonia (PJP) and varicella-zoster virus (VZV) prophylaxis are recommended.
• Intravenous immunoglobulin (IVIG) replacement is recommended as primary prophylaxis during or shortly after TCE treatment (LE: 1).
• Talquetamab-associated toxicities include dry mouth, skin rash, skin desquamation, and nail disorders.
Monoclonal antibody and ADC treatment considerations
• Subcutaneous daratumumab is preferred over intravenous administration because of its administration convenience and improved safety profile (LE: 2).
• Anti-CD38 therapies, including daratumumab and isatuximab, can interfere with red blood cell antibody testing for up to six months after the last dose.
• Patients receiving anti-CD38 therapy should receive a medical alert card, and the local blood bank should be informed.
• Hepatitis B screening is recommended before anti-CD38 monoclonal antibody treatment.
• VZV prophylaxis is recommended for patients receiving monoclonal antibody therapy.
• IVIG may be administered to patients with hypogammaglobulinemia and recurrent infections.
• Belantamab mafodotin is associated with ocular AEs, including blurred vision, dry eyes, photophobia, eye irritation, and cataracts. The associated REMS program should be followed closely.
• Daratumumab and isatuximab may interfere with serum protein electrophoresis and immunofixation assays, requiring appropriate interference testing or alternative assessment methods.
Patient education and quality of life
• Patients and caregivers should receive treatment-specific education regarding expected toxicities, warning signs, treatment logistics, and follow-up care.
• Patients receiving CAR T-cell or TCE therapy should be educated about CRS, ICANS, delayed neurological toxicities, and infection risks.
• Following CAR T-cell infusion, patients and caregivers should remain within approximately 1–2 hours of the treating hospital for at least two weeks, with caregiver availability.
• Discussions should address treatment center accessibility, travel, lodging, financial support, and caregiver availability.
• Clinicians should periodically assess patients' QOL, including physical functioning, psychological well-being, treatment-related symptoms, and financial concerns.
• Seasonal vaccinations and appropriate infection prophylaxis are recommended according to the guideline recommendations.
Racial and ethnic disparities
• Black patients have a higher incidence of MM than White patients but have historically been underrepresented in clinical trials of approved treatments.
• Approximately 4%–8% of participants in various landmark clinical trials were Black.
• Disparities in access to newer treatments, including CAR T-cell and TCE therapies, have also been reported.
• Clinicians should consider strategies to improve treatment access, patient care, and representation in clinical trials and real-world studies.
Strengths
• Multidisciplinary and balanced expert panel involving medical oncology, nursing, patient advocacy, and other relevant specialties.
• Guideline development followed the IOM Standards for Developing Trustworthy Clinical Practice Guidelines.
• Recommendations incorporated literature evidence and expert clinical experience.
• A modified Delphi process was used, with a minimum consensus threshold of 85%.
• Evidence was graded using the OCEBM Levels of Evidence framework.
• The draft guideline underwent external public review.
• Conflict-of-interest disclosures and management procedures were implemented.
• The guideline received financial support solely from SITC, with no commercial funding.
Limitations
• Evidence is limited regarding the optimal selection and sequencing of bridging therapy before CAR T-cell treatment.
• The optimal recovery period for T-cell function before CAR T-cell therapy has not been established.
• The mechanisms of resistance to CAR T-cell and TCE therapies are not fully understood.
• Data regarding treatment efficacy and safety are limited for certain special populations, including patients with CNS involvement, PCL, renal impairment, and concurrent AL amyloidosis.
• Data on TCE efficacy in patients with high-risk disease are limited.
• The optimal management strategies for delayed neurological toxicities following CAR T-cell therapy remain unknown.
• The utility and optimal timing of vaccination following CAR T-cell therapy remain uncertain.
• Additional studies are needed to clarify treatment sequencing and outcomes following progression on TCE therapy.
Why this clinical practice guideline matters
The SITC clinical practice guideline provides evidence-based and expert consensus-based recommendations for the use of approved immunotherapies in patients with newly diagnosed and relapsed/refractory multiple myeloma, covering CAR T-cell therapies, TCE bispecific antibodies, ADCs, and monoclonal antibody-based combinations. It addresses treatment selection and sequencing, special patient populations, toxicity management, infection prevention, and patient education, while identifying areas where clinical evidence remains limited. Although MM remains incurable, the guideline describes the expanding immunotherapy treatment options and emphasizes the need for continued research to address treatment-related challenges and improve clinical management.
Reference:
Lin Y, Aiello J, Avigan D, Berdeja JG, Biru Y, Chari A, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of multiple myeloma, version 2.0. Journal for ImmunoTherapy of Cancer. 2026;14:e016142. https://doi.org/10.1136/jitc-2026-016142
Review
Monoclonal Gammopathy in Autoimmune Diseases: Marker, Consequence, Pathogenetic Factor—Or Coincidence? — Biomedicines (October 2026)
What is the purpose of the review?
To examine the epidemiological, clinical, and biological relationship between monoclonal gammopathy and autoimmune or immune-mediated diseases. It evaluates potential mechanisms, clinical implications, approaches to screening and monitoring, and priorities for future research, including the relationship between chronic inflammation and clonal B-cell and plasma-cell disorders.
Summary
The review synthesizes evidence on the association between monoclonal gammopathy and autoimmune diseases, including primary Sjögren’s syndrome (SS), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA), and discusses four potentially overlapping explanations: monoclonal gammopathy as a marker of chronic immune activation, a consequence of persistent inflammation, a pathogenic factor, or a coincidental finding. Although some observational studies report increased prevalence of monoclonal gammopathy in specific autoimmune diseases, the population-based iStopMM study, which screened more than 75,000 individuals, found no significant association between autoimmune disease history and screen-detected monoclonal gammopathy of undetermined significance (MGUS) after adjustment for age and sex. The review also addresses clinical risk assessment, monitoring, treatment considerations, and future research into single-cell and spatial omics, the BAFF/APRIL signaling pathway, and PANoptosis.
Key points
Epidemiological associations vary by disease
• Primary SS has a reported monoclonal gammopathy prevalence ranging from 7.4% in a cohort of 352 patients to approximately 22% in other cohorts.
• A systematic review and meta-analysis reported the highest relative association with monoclonal gammopathy among autoimmune inflammatory rheumatic diseases for SS (OR 4.51, 95% CI 3.39–5.74).
• In the iStopMM study, autoimmune disease history was not significantly associated with screen-detected MGUS after adjustment for age and sex, despite an association with previously clinically diagnosed MGUS.
Four models may explain the relationship
• Monoclonal gammopathy may indicate chronic immune activation.
• Persistent autoimmune inflammation may contribute to clonal B-cell or plasma-cell expansion.
• Monoclonal immunoglobulins or the underlying clone may directly cause organ damage, as recognized in monoclonal gammopathy of clinical significance (MGCS), including monoclonal gammopathy of renal significance (MGRS).
• Monoclonal gammopathy and autoimmune disease may occur coincidentally because of shared factors such as age, genetic background, or increased diagnostic surveillance.
Potential biological mechanisms
Chronic antigen stimulation, sustained B-cell activation, germinal-center dysregulation, increased T follicular helper cell activity, and BAFF/APRIL-, IL-6-, NF-κB-, and STAT3-mediated signaling.
Clinical implications differ across conditions
• In primary SS, monoclonal gammopathy has been associated with greater disease activity and increased risk of lymphoma and other hematologic malignancies.
• In chronic hepatitis C virus (HCV) infection, one prospective study found monoclonal gammopathy in 11% of HCV-positive patients with chronic liver disease, compared with 1% of HCV-negative controls.
• Associations involving autoimmune hepatitis, primary biliary cholangitis, psoriasis, and other immune-mediated diseases remain less clearly established or require further investigation.
Screening and monitoring recommendations are risk-based
• Current evidence does not support routine monoclonal gammopathy screening for every patient with autoimmune or immune-mediated disease.
• Targeted testing may be considered in selected clinical settings, including primary SS or SLE accompanied by unexplained hypergammaglobulinemia, cytopenias, renal dysfunction, or unusual systemic symptoms.
• MGUS monitoring should follow established hematologic risk-stratification criteria, incorporating M-protein levels, immunoglobulin isotype, free light chain ratio, and evidence of organ damage. Risk factors should be reassessed over time.
Treatment evidence remains limited
• MGUS alone is not considered a contraindication to modern immunomodulatory or biologic therapies.
• MGUS has been reported following anti-TNF therapy in patients with RA and psoriasis, but a causal relationship has not been established.
• There is insufficient evidence that conventional disease-modifying antirheumatic drugs (DMARDs), glucocorticoids, or biologic therapies prevent MGUS or halt progression to multiple myeloma (MM).
• Emerging B-cell- and plasma-cell-directed therapies remain investigational for modifying the course of coexisting autoimmune disease and MGUS; they are not established treatments for otherwise asymptomatic MGUS.
Future research priorities
Prospective disease-specific cohorts, longitudinal single-cell and spatial omics, B-cell receptor repertoire analysis, investigation of the BAFF/APRIL axis, and evaluation of PANoptosis as a potential link between chronic inflammation and clonal plasma-cell disorders.
Strengths
Integration of epidemiological, clinical, and mechanistic evidence; comparison of population-based screening findings with clinically identified cohorts; and discussion of diagnostic, prognostic, and therapeutic implications across multiple disease groups.
Limitations and evidence gaps
The review identifies conflicting findings across observational cohorts, potential ascertainment bias, uncertainty about causal relationships, limited prospective and disease-specific evidence, and insufficient data on the effects of immunomodulatory treatments on MGUS progression. It also notes that longitudinal single-cell data specifically addressing autoimmune-associated MGUS remains scarce.
Why this review matters
The relationship between monoclonal gammopathy and autoimmune or immune-mediated diseases is heterogeneous, and current evidence does not establish a uniform causal relationship or consistent progression risk across these conditions. Routine screening of all patients with autoimmune disease is not supported by the available evidence; testing should be guided by the underlying disease and relevant clinical or laboratory findings, while confirmed MGUS should be monitored using established hematologic risk-stratification criteria and periodic reassessment. Further prospective and molecular studies are needed to clarify disease-specific risks, distinguish coincidental associations from biologically meaningful relationships, and determine whether targeted diagnostic or therapeutic approaches can improve clinical management.
Reference:
Műzes, G., & Sipos, F. (2026). Monoclonal Gammopathy in Autoimmune Diseases: Marker, Consequence, Pathogenetic Factor—Or Coincidence? Biomedicines, 14(10), 2288. https://doi.org/10.3390/biomedicines14102288
Advancing T Cell Engagers in Multiple Myeloma: Structural Design and Clinical Optimization to Address Current Limitations — Drug Design, Development and Therapy (October 2026)
What is the purpose of the review?
This review examines advances in the structural design and clinical optimization of T cell engagers (TCEs) for multiple myeloma (MM), including molecular engineering, antigen selection, dosing strategies, toxicity management, and combination therapies. It evaluates clinical outcomes, mechanisms of treatment resistance, persistent safety concerns, and emerging approaches to improve response durability and guide treatment sequencing.
Summary
T cell engagers (TCEs) are engineered immunotherapies that bind a tumor-associated antigen and CD3 on T cells, bringing immune cells into contact with multiple myeloma cells to promote tumor-cell killing. Four TCEs (teclistamab, elranatamab, talquetamab, and linvoseltamab) are identified in the review as approved for MM; in heavily pretreated patients with relapsed or refractory MM (RRMM), conventional B-cell maturation antigen (BCMA)-targeting agents demonstrated overall response rates (ORRs) of 61–74% and median progression-free survival (mPFS) of 11–17 months, while the GPRC5D-targeting agent talquetamab demonstrated an ORR of approximately 69–74% and an mPFS of approximately 11 months. The review discusses advances in antibody engineering, earlier-line treatment, step-up dosing, and combination therapies, while highlighting unresolved challenges, including antigen escape, cytokine release syndrome (CRS), infections, T-cell exhaustion, prolonged immunosuppression, uncertain treatment sequencing, manufacturing complexity, cost, and accessibility.
Key points
Structural design and molecular engineering
• TCEs are engineered molecules that bind a tumor-associated antigen and an activating receptor, typically CD3, on T cells to facilitate T-cell-mediated tumor killing.
• IgG-like formats typically have serum half-lives of 7–14 days and support subcutaneous administration. Non-IgG-like formats generally have shorter half-lives; blinatumomab, a CD19×CD3 TCE used in B-cell acute lymphoblastic leukemia, has a reported half-life of approximately 2–3 hours.
• The principal validated targets discussed for MM are BCMA, GPRC5D, and FcRH5. BCMA is a major therapeutic target; GPRC5D provides an alternative for some patients with BCMA-refractory disease, and FcRH5 is being investigated as another target.
• Emerging molecular designs include multivalent formats such as alnuctamab, which uses a 2+1 configuration with two BCMA-binding arms and one CD3-binding arm, and trispecific TCEs such as ramantamig (BCMA×GPRC5D×CD3).
• Conditional activation, logic-gated constructs, and TCEs conjugated to cytotoxic or immunomodulatory payloads are being investigated to improve tumor selectivity or modify antitumor activity. Many of these approaches remain in preclinical or early clinical development.
Clinical efficacy
• The review identifies four TCEs approved for MM: teclistamab, elranatamab, talquetamab, and linvoseltamab. Their approved indications and treatment settings should be distinguished when making agent-specific clinical decisions.
• In late-stage RRMM, defined in the review as disease following at least three prior treatment lines, conventional BCMA-targeting TCEs demonstrated ORRs of 61–74% and mPFS of 11–17 months.
• Linvoseltamab demonstrated a median duration of response approaching 29 months in the reported data.
• In patients with prior BCMA-targeted therapy, the GPRC5D-targeting agent talquetamab demonstrated an ORR of approximately 69–74% and an mPFS of approximately 11 months.
• Early-phase studies of investigational multispecific TCEs reported ORRs of approximately 73–86% for ramantamig and 75% for ISB 2001. These are study-specific findings and should not be interpreted as direct evidence of superiority over approved agents.
Safety and adverse events
• Cytokine release syndrome (CRS) is a major adverse event associated with TCE therapy. It commonly occurs during step-up dosing or after the first full dose. The review reports that CRS is predominantly grade 1–2, with less than 1% grade 3 in one discussion; elsewhere, it reports grade ≥3 CRS rates of 0.6–4.3%. These estimates arise from different cited clinical data and should not be treated as a single pooled rate.
• Immune effector cell-associated neurotoxicity syndrome (ICANS) is also reported. In a real-world comparative study using propensity score matching (262 patients per group), the risk of ICANS did not differ significantly between teclistamab and BCMA-targeting chimeric antigen receptor (CAR) T-cell therapy (hazard ratio [HR] = 1.12).
• Infections and hematologic toxicities, including neutropenia and anemia, are important safety concerns. The review reports grade 3–4 infections in approximately 30–45% of patients in cited clinical data. Separately, it reports an overall infection rate of approximately 56%, with 24% grade ≥3 infections, among patients receiving anti-BCMA agents. These figures describe different reported datasets and populations.
• BCMA-targeting therapies are associated with B-cell depletion and hypogammaglobulinemia, which contribute to infection risk. The review reports that median B-cell recovery can exceed 12 months after treatment discontinuation.
• GPRC5D-targeting therapies can cause taste disturbances (dysgeusia), dry mouth, hair loss, skin changes, and nail disorders because GPRC5D is also expressed in certain normal epithelial tissues.
• Risk-management strategies include step-up dosing, premedication, clinical monitoring, tocilizumab or corticosteroids when indicated, immunoglobulin replacement, antimicrobial prophylaxis, and supportive care.
Clinical optimization and combination strategies
• Earlier-line treatment: The review discusses moving TCEs into earlier treatment settings to take advantage of potentially better-preserved T-cell function. In the MajesTEC-1 trial, patients receiving teclistamab after fewer than three prior lines of therapy had higher response rates than those who had received more prior treatment.
• Post-transplant and newly diagnosed disease: Phase 3 trials are investigating TCEs as maintenance therapy after autologous stem cell transplantation (ASCT) and as part of treatment regimens for newly diagnosed MM. Examples include MajesTEC-4, MagnetisMM-7, MajesTEC-5, MajesTEC-7, and MagnetisMM-6.
• Combination therapies: Investigational strategies include combining BCMA-targeting TCEs with gamma-secretase inhibitors such as nirogacestat, immunomodulatory drugs (IMiDs) such as pomalidomide, anti-CD38 monoclonal antibodies, and immune checkpoint inhibitors.
• MonumenTAL-2: The combination of talquetamab and pomalidomide achieved an ORR of up to 86.7% and a 6-month progression-free survival rate of 93.3% in the reported study data.
• Treatment sequencing: The optimal sequence of TCEs, CAR T-cell therapy, and transplantation remains uncertain. The review notes concerns that previous TCE exposure may affect subsequent CAR T-cell efficacy, but this question requires further investigation.
Scope and coverage
• Integrates molecular engineering principles with clinical application, including structural design, target selection, treatment optimization, and adverse event management.
• Discusses approved TCEs, investigational agents, clinical trial findings, emerging treatment strategies, manufacturing challenges, costs, and accessibility.
Limitations
• Approximately 30% of patients experience primary resistance to TCE therapy, and most patients who initially respond eventually relapse.
• Antigen loss and lineage plasticity can contribute to treatment resistance.
• T-cell exhaustion, prolonged B-cell depletion, hypogammaglobulinemia, infection risk, and on-target/off-tumor toxicity remain significant concerns.
• Predictive biomarkers for response, toxicity, and treatment sequencing are lacking.
• The optimal sequencing of TCEs with CAR T-cell therapy and transplantation remains undefined.
• Multispecific formats introduce manufacturing complexity, while treatment costs and the need for specialized centers limit accessibility, particularly in resource-constrained settings.
• Head-to-head comparative trials and mature phase 3 data on combination regimens are needed before definitive treatment algorithms can be established.
Why this review matters
TCEs are approved treatment options for multiple myeloma in specified clinical settings, with reported antitumor activity in heavily pretreated patients and ongoing investigation of multispecific formats and combination regimens. Their use is associated with CRS, infections, hypogammaglobulinemia, hematologic toxicities, and target-specific adverse events, while antigen escape, relapse, and T-cell exhaustion remain unresolved challenges. Further evidence is needed to establish optimal treatment sequencing, validate predictive biomarkers, assess combination regimens and earlier-line use, and clarify long-term safety, comparative effectiveness, cost, and accessibility.
Reference:
Cai L, Ding Y, Wang J, Quan L, Li Q, Wang G, Ma C, Sun C, Hu Y. Advancing T Cell Engagers in Multiple Myeloma: Structural Design and Clinical Optimization to Address Current Limitations. Drug Des Devel Ther. 2026;20:638795 https://doi.org/10.2147/DDDT.S638795
Extramedullary Disease and Prolonged Hematotoxicity After Standard-of-Care Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: A Transatlantic Real-World Evidence Synthesis — Current Oncology (October 2026)
What is the purpose of the review?
To synthesize real-world evidence on the efficacy and prolonged hematologic toxicities of idecabtagene vicleucel (ide-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in patients with relapsed/refractory multiple myeloma (RRMM). The study specifically evaluates the association of extramedullary disease (EMD) with treatment response and progression-free survival (PFS), and characterized prolonged cytopenias following treatment.
Summary
This focused evidence synthesis included five retrospective, observational real-world studies. Across two non-overlapping ide-cel cohorts, EMD was reported in 111 of 510 infused patients (21.8%) and was associated with shorter median PFS than the absence of EMD: 6.21 versus 14.82 months in the French FENIX/DESCAR-T cohort and 5.30 versus 11.10 months in the US cohort. Grade 3 or higher cytopenias remained common at day 90, with severe thrombocytopenia reported in 20.8–27.7% of patients across ide-cel-only hematotoxicity studies; high baseline bone marrow plasma-cell burden, rather than EMD independently, predicted prolonged severe cytopenias in the adjusted analysis.
Key points
• Study design: Focused descriptive evidence synthesis of five real-world observational studies of standard-of-care ide-cel in patients with RRMM. The literature search was conducted in PubMed on May 6, 2026.
• EMD prevalence: Among two non-overlapping ide-cel cohorts, 111 of 510 infused patients (21.8%) reported EMD. Prevalence was 17.0% in the French registry and 23.9% in the US cohort.
• Progression-free survival: Median PFS was shorter in patients with EMD than in those without EMD in both cohorts:
- French FENIX/DESCAR-T cohort: 6.21 versus 14.82 months; adjusted hazard ratio (HR) 3.15 (95% CI 1.82–5.47; p < 0.0001).
- US EMD-focused cohort: 5.30 versus 11.10 months; adjusted HR 1.50 (95% CI 1.10–2.20; p = 0.02).
• Treatment response: In the US EMD-focused cohort, the day-90 overall response rate (ORR) was 52% among patients with EMD versus 82% among those without EMD. In a supportive mixed-product cohort, the best ORR among ide-cel-treated patients with EMD was 61%, defined as partial response or better according to International Myeloma Working Group (IMWG) criteria.
• Prolonged cytopenias: Grade 3 or higher cytopenia affected 64.7% of patients at day 30 and 40.4% at day 90 in the cytopenia-focused cohort. Grade 3 or higher thrombocytopenia at day 90 was reported in 20.8–27.7% across ide-cel-only hematotoxicity studies.
• Predictors of hematotoxicity: Baseline bone marrow plasma-cell burden of at least 50% independently predicted day-90 severe cytopenias (OR 6.40; 95% CI 1.40–33.60). EMD did not independently predict prolonged cytopenia after adjustment for baseline blood counts and bone marrow involvement.
• Supportive care: Reported interventions included granulocyte colony-stimulating factor (G-CSF), blood transfusions, thrombopoietin agonists, intravenous immunoglobulin (IVIG), and stem-cell boosts.
Strengths
• Primary EMD analyses were restricted to non-overlapping ide-cel cohorts to reduce duplicate patient counting.
• Two investigators independently performed study selection and data extraction, resolving discrepancies by consensus.
• Study quality was assessed using the National Institutes of Health (NIH) Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies.
• EMD-associated PFS outcomes were evaluated across independent cohorts without mathematically pooling study-specific medians or hazard ratios.
Limitations
• The review was a focused evidence synthesis rather than an exhaustive systematic review or meta-analysis, and the literature search was limited to PubMed on a single date.
• All included studies were retrospective and observational, with potential residual confounding.
• EMD definitions, imaging assessments, hematotoxicity criteria, and reporting periods varied across studies.
• The primary EMD efficacy analysis included only two independent cohorts, while the hematotoxicity analysis relied primarily on one cohort.
• Some registry classifications could not be centrally reviewed to confirm exclusion of bone-contiguous paraskeletal lesions.
• Potential patient overlap remained between efficacy and toxicity datasets.
• Landmark cytopenia rates reflected surviving, evaluable patients at specific time points rather than continuous follow-up of cytopenia persistence.
• Analyses were descriptive and observed post-infusion outcomes did not include patients who failed to reach infusion.
Why this review matters
In real-world patients with RRMM treated with ide-cel, EMD was consistently associated with inferior PFS and lower day-90 response rates, while severe cytopenias remained common three months after treatment. High baseline bone marrow plasma-cell burden independently predicted prolonged severe cytopenias in the reported adjusted analysis, whereas EMD did not independently predict this outcome after adjustment. These findings are based on retrospective observational evidence and support assessing EMD status, bone marrow disease burden, and hematopoietic reserve before infusion, while prospective studies are needed to evaluate strategies for improving outcomes.
Reference:
Soomro, M. A., Khaliq, A., Bilal Abid, M., Paul, B., Atrash, S., Shaikh, H., Mazloom, A., Alkharabsheh, O., Mewawalla, P., Shah, M. R., Khan, A. M., Mahmoudjafari, Z., Mushtaq, M. U., Kort, J., Habib, A., & Abdallah, A.-O. (2026). Extramedullary Disease and Prolonged Hematotoxicity After Standard-of-Care Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: A Transatlantic Real-World Evidence Synthesis. Current Oncology, 33(11), 642. https://doi.org/10.3390/curroncol33110642
Multiple Myeloma Measurable Residual Disease: Spotting Three Different Detection Methods — International Journal of Molecular Sciences (October 2026)
What is the purpose of the review?
To examine three technologies used to assess measurable residual disease (MRD) in multiple myeloma (MM): next-generation flow cytometry (NGF), next-generation sequencing (NGS), and mass spectrometry (MS). It compares their analytical performance, sensitivity, standardization, pre-analytical requirements, clinical validation, and limitations, while evaluating the roles of cytogenetic risk assessment, disease heterogeneity, and combined bone marrow– and blood-based testing.
Summary
The authors conducted a narrative review of English-language publications from January 2014 to May 2026, searched through PubMed/MEDLINE, Scopus, and Web of Science, supplemented by manual reference screening and selected earlier landmark studies. The review identifies NGF and clonotype-based NGS as the reference methods for bone marrow MRD assessment in MM; MRD negativity at a sensitivity of at least 10-5 is associated with longer progression-free survival (PFS) and overall survival (OS), while deeper and sustained MRD negativity may provide additional prognostic information. MS detects patient-specific monoclonal immunoglobulins or their characteristic peptides in peripheral blood and enables less invasive monitoring, but it does not replace marrow-based testing under current International Myeloma Working Group (IMWG) criteria because of limitations in standardization, validation, and detection of some disease patterns. The review also examines the potential value of combining marrow-based testing, blood-based assays, and imaging, while noting that this approach requires prospective validation before routine clinical use.
Key points
Role and clinical significance of MRD
• The IMWG defines undetectable MRD as the absence of detectable myeloma cells among at least 100,000 bone marrow cells, corresponding to an assay limit of detection (LOD) of at least 10-5.
• MRD negativity is associated with longer PFS and OS, independently of cytogenetic risk and disease stage.
• Sustained MRD negativity over time is associated with significantly longer PFS, regardless of treatment received.
• Greater analytical sensitivity may improve prognostic assessment. The review reports better survival outcomes at a detection threshold of 10-6 than at 10-5, particularly in high-risk patients; an LOD of 10-7 may provide further prognostic information. However, such highly sensitive testing is technically demanding and may be difficult to implement outside clinical trials.
• The US Food and Drug Administration (FDA) accepted MRD negativity as an early endpoint to support accelerated approval of MM treatments in 2024 and issued draft guidance in 2026 recommending MRD and complete response (CR) as primary endpoints in MM trials.
• Important distinction: The prognostic association between MRD negativity and survival, its use as a clinical trial endpoint, and its use to guide individual treatment decisions are separate applications. The latter remains under investigation.
Next-generation flow cytometry (NGF)
• Method: NGF identifies abnormal plasma cells using antibody-based flow cytometry. The standardized EuroFlow protocol uses two tubes with eight-color antibody panels.
• Analytical performance: EuroFlow-NGF has an LOD of 2× 10-6 and a limit of quantification (LOQ) of 5× 10-6. These values describe analytical detection and quantification, not the ability to predict clinical outcomes.
• Strengths: NGF is widely applicable, does not require a baseline diagnostic sample, and typically provides results within 3–4 hours. It is generally faster and less expensive than NGS for MRD detection.
• Limitations: It requires fresh bone marrow samples, standardized laboratory procedures, and trained personnel. Hemodilution and treatment-related changes in plasma-cell antigen expression may affect assessment.
• Clinical evidence: Studies have reported concordance rates often exceeding 85% between NGF and NGS when both are performed on the same bone marrow sample at a sensitivity of 10-5. A 2026 multicenter Italian study and a prospective comparison within the phase III EMN24-ISKIA trial are discussed in relation to NGF performance.
• Interpretation: Although NGF and NGS generally show similar performance, their results may differ in some patients or cytogenetic subgroups. Neither method eliminates the limitations associated with sampling a single bone marrow site. NGF and NGS generally show similar performance; their results may differ in some patients or cytogenetic subgroups. Neither method eliminates the limitations associated with sampling a single bone marrow site. the limitations associated with sampling a single bone marrow site.
Next-generation sequencing (NGS)
• Method: Clonotype-based NGS identifies clonal immunoglobulin gene rearrangements, including IGH, IGK, and, less commonly, IGL, in a baseline sample and tracks these rearrangements in subsequent samples.
• Analytical performance: The reported LOD is approximately 10-6, although achievable sensitivity depends on the amount of DNA and the number of cells analyzed.
• Strengths: NGS enables sensitive tracking of a patient's specific tumor clone over time and can provide reproducible results across centers. It can also be performed on stored samples.
• Limitations: MRD tracking requires identification of a baseline clonotype. High costs, slower processing, complex data analysis, and standardization challenges limit routine implementation.
• Important distinction: Clonotype-based NGS for MRD assessment differs from genomic profiling, which identifies mutations, copy-number alterations, and structural variants for biological characterization, risk stratification, and potential treatment selection. The review identifies clonotype-based NGS, rather than genomic profiling, as the NGS approach currently validated for MRD assessment.
Mass spectrometry (MS)
• Method: MS detects patient-specific monoclonal immunoglobulins or characteristic peptides in peripheral blood. Approaches discussed include MALDI-TOF, EXENT, EasyM, and M-InSight.
• Analytical performance: MS can detect monoclonal proteins at concentrations below the detection limits of conventional serum protein electrophoresis and immunofixation methods. Some MS assays approach the sensitivity of NGS-based MRD assessment, but the values are not directly comparable because MS measures circulating proteins while NGF and NGS detect or track tumor cells.
• Strengths: MS allows repeated blood-based monitoring without bone marrow aspiration. Depending on the assay, it can distinguish a patient's monoclonal protein from therapeutic monoclonal antibodies and may detect recurrence earlier than conventional serological methods.
• Clinical evidence: In a pooled analysis of patients treated with carfilzomib-based regimens, patients who were negative on both LC-MS and NGS at the 10-6 threshold had a five-year PFS rate of 89%. This result applies to that analyzed patient group and should not be interpreted as an outcome estimate for all patients with MM.
• Limitations: Assay protocols and reporting thresholds are not harmonized internationally. Some methods require a baseline diagnostic sample to identify the patient's specific clonotypic peptide. Blood-based protein measurements may not reflect bone marrow tumor burden, particularly in oligo-secretory or non-secretory disease. Clinical-grade, regulatory-approved assays remain limited.
• Current status: MS is a complementary monitoring method, not a replacement for NGF or NGS under current IMWG MRD criteria.
Disease heterogeneity and combined testing
• Multiple myeloma may be unevenly distributed across bone marrow, peripheral blood, and extramedullary sites. Consequently, a single bone marrow aspirate may not capture all residual disease.
• The review reports that blood-based tests fail to detect residual disease identified in bone marrow in approximately 8–21% of patients.
• Discordant results do not necessarily indicate technical error: they may reflect differences in disease distribution, tumor biology, or the behavior of circulating monoclonal proteins.
• Positron emission tomography/computed tomography (PET/CT) and diffusion-weighted magnetic resonance imaging (MRI) provide complementary information about disease outside sampled bone marrow. Imaging results should be interpreted alongside laboratory-based MRD findings.
• Combining marrow-based NGF or NGS with blood-based MS may improve residual disease detection. However, the combined approach has been examined mainly in retrospective or post hoc analyses and has not been validated prospectively in multicenter trials. It is therefore currently intended for clinical research rather than routine treatment decisions.
• Circulating cell-free DNA (cfDNA) and extracellular vesicles are also under investigation, particularly for heterogeneous, relapsed, or extramedullary disease. Neither approach is validated for routine MRD assessment.
Artificial intelligence and future directions
• Artificial intelligence (AI) and machine-learning methods are being explored for MRD analysis, risk stratification, and integration of heterogeneous clinical and laboratory data.
• Potential applications include reducing manual workload and variability and supporting more standardized analysis across laboratories.
• The review emphasizes that algorithms and machine-learning models require appropriate standardization and validation before they can reliably support clinical decisions.
• Priorities include prospective validation of MRD sensitivity thresholds, harmonization of MS methods, development of blood-based assays, and evaluation of MRD-guided treatment strategies.
• Changes to treatment based on MRD results, including treatment intensification or discontinuation, remain under investigation and should preferably occur within clinical trials until sufficient evidence is available.
Strengths
• Compares NGF, NGS, and MS using common analytical, pre-analytical, and regulatory criteria.
• Distinguishes analytical sensitivity from clinical sensitivity and separates clonotype-based NGS for MRD from genomic profiling.
• Draws on consensus statements and guidelines from the IMWG, European Hematology Association–European Myeloma Network (EHA-EMN), and FDA, as well as prospective trials, large retrospective series, and analytical validation studies.
• Examines discordant results across bone marrow, blood, and imaging, including the implications of spatial disease heterogeneity.
Limitations
• The study is a narrative review, not a formal systematic review or meta-analysis; no pooled estimate was calculated by the review itself.
• The authors prioritized consensus statements, guidelines, prospective trials, large retrospective series, and analytical validation studies. Selected congress abstracts and older landmark studies were also included where relevant.
• Evidence for combined marrow-based and blood-based MRD assessment is derived mainly from retrospective or post hoc analyses and has not been validated prospectively in multicenter trials.
• MS studies use heterogeneous assays and thresholds, and much of the evidence comes from retrospective cohorts and research-use platforms.
• Evidence for some emerging approaches, including cfDNA and extracellular vesicles, comes from small series and individual cases.
Why this review matters
NGF and clonotype-based NGS remain the reference methods for MRD assessment in multiple myeloma, and MRD negativity is consistently associated with longer PFS and OS. MS provides a less invasive approach for monitoring circulating monoclonal proteins, but its analytical measurements are not directly equivalent to cell-based MRD results, and it has not replaced marrow-based testing under current IMWG criteria. Combining bone marrow assessment, blood-based testing, and imaging may improve disease evaluation, but prospective multicenter validation is needed before composite MRD approaches can be used routinely to guide treatment.
Reference:
Tartaglione, S., Tagliaferro, M., Scerpa, M. C., Basile, V., D’Ambrosio, F., Natali, P., Marino, M., Equitani, F., Maurillo, L., & Basile, U. (2026). Multiple Myeloma Measurable Residual Disease: Spotting Three Different Detection Methods. International Journal of Molecular Sciences, 27(21), 9447. https://doi.org/10.3390/ijms27219447
Diagnosis and management of monoclonal gammopathies — CMAJ (November 2026)
What is the purpose of the review?
To review current evidence and clinical practice guidelines on the recognition, diagnosis, initial evaluation, and monitoring of monoclonal gammopathies, particularly monoclonal gammopathy of undetermined significance (MGUS). The review aims to guide general practitioners in identifying patients with possible monoclonal gammopathy of clinical significance (MGCS), multiple myeloma, or other lymphoproliferative disorders, and determining when hematology referral is necessary.
Summary
This focused literature review examined current evidence and clinical practice guidelines on MGUS and related monoclonal gammopathies. The authors searched PubMed from inception through March 6, 2025, emphasizing clinical practice guidelines and clinical evidence published from 2019 onward; the article describes a focused literature review rather than a systematic review or meta-analysis. It discusses clinical warning signs, diagnostic investigations, progression risks, hematology referral criteria, and monitoring recommendations, while identifying uncertainties regarding MGUS screening and follow-up.
Key points
MGUS and risk of progression
• MGUS is a common, asymptomatic premalignant condition frequently detected incidentally during investigations for anemia, kidney dysfunction, or bone lesions.
• MGUS carries a risk of progression to MGCS, multiple myeloma, Waldenström macroglobulinemia, lymphoma, and other related disorders.
• MGUS prevalence increases with age:
- 2% among adults aged 40–59 years
- 3%–6% among adults aged 60–79 years
- 7%–13% among adults aged 80 years or older
• The overall risk of progression is approximately 1% per year.
• Light-chain MGUS has a lower average progression risk of approximately 0.3% per year.
Clinical features requiring investigation
• Monoclonal gammopathies should be considered in patients with otherwise unexplained:
- Anemia, particularly hemoglobin below 100 g/L or more than 20 g/L below the lower limit of normal
- Acute or chronic kidney dysfunction, proteinuria, or microscopic hematuria
- Persistent focal bone pain, pathological fractures, or osteolytic lesions
- Hypercalcemia
- Progressive motor, peripheral, or autonomic neuropathy
- Cardiomyopathy or other features suggestive of AL amyloidosis.
- Unexplained lymphadenopathy, hepatosplenomegaly, constitutional symptoms, or hyperviscosity
• MGCS should be suspected when a small plasma-cell or B-cell clone produces a monoclonal protein that causes organ injury, even when diagnostic criteria for multiple myeloma or lymphoma are not met.
Initial diagnostic investigations
• Initial investigations for suspected monoclonal gammopathy should include:
- Complete blood count, creatinine, and serum calcium
- Serum protein electrophoresis (SPEP)
- Serum immunofixation (sIFE)
- Serum free light chains (sFLC)
- Quantitative immunoglobulins
• Combining SPEP, sIFE, and sFLC can detect monoclonal proteins in approximately 99.5% of cases.
• sFLC results should be interpreted using reference ranges that account for kidney function.
• Additional investigations, including urine protein electrophoresis, urine immunofixation, kidney biopsy, skeletal imaging, and bone marrow examination, depend on clinical findings and suspected organ involvement.
• Routine MGUS screening is not recommended for asymptomatic individuals because clinical benefit has not been established.
Classification and progression risk
• MGUS is defined by:
- Serum Mprotein below 30 g/L (3 g/dL)
- Fewer than 10% clonal plasma cells in bone marrow, if assessed
- Absence of myeloma-defining end-organ damage or another lymphoproliferative neoplasm
• MGUS is classified as non-IgM, IgM, or light-chain MGUS.
• The Mayo Clinic risk model identifies three progression risk factors:
- Mprotein of 15 g/L (1.5 g/dL) or higher
- Non-IgG isotype (IgA or IgM)
- Abnormal sFLC ratio
• The estimated 20-year absolute progression risk ranges from approximately 5% with no risk factors to 58% with all three risk factors.
Hematology referral and monitoring
• All patients with a newly detected M-protein or unexplained abnormal sFLC ratio suggestive of clonality should be referred to hematology for further assessment.
• Following initial hematology assessment, selected patients with confirmed low-risk MGUS and no clinical or laboratory findings requiring specialist follow-up may be monitored in primary care.
• Recommended monitoring includes:
- Repeat clinical assessment and laboratory testing (complete blood count, creatinine, calcium, SPEP, and sFLC) 6 months after the initial MGUS diagnosis.
- If stable, patients with low-risk MGUS may be followed every 2–3 years.
• The low-risk MGUS criteria specified in the review are:
- Mprotein below 15 g/L (1.5 g/dL)
- IgG isotype
- Normal sFLC ratio
• Patients with intermediate- or high-risk MGUS, IgM MGUS with symptoms suggestive of hyperviscosity, suspected MGCS, or other concerning clinical or laboratory findings should remain under hematology follow-up.
• Hematology reassessment is recommended for patients monitored in primary care who develop new clinical warning signs or concerning laboratory changes, including:
- Significant M-protein increase (e.g., greater than 5 g/L).
- Markedly abnormal involved-to-uninvolved sFLC ratio (e.g., greater than 8).
Review characteristics and evidence limitations
Review characteristics
• The review incorporates clinical practice guidelines and clinical evidence, with emphasis on publications from 2019 onward.
• It addresses MGUS and related monoclonal gammopathies to support clinical recognition, initial evaluation, differential diagnosis, and referral decisions.
• It provides practical clinical guidance on diagnostic investigations, progression risk stratification, and follow-up in general practice.
Limitations and uncertainties
• Evidence that MGUS follow-up improves patient-centred outcomes remains limited and is largely observational.
• Whether MGUS screening or structured follow-up improves clinical outcomes remains uncertain.
• The optimal monitoring intensity for low-risk MGUS has not been established.
• Observational studies suggesting benefits from earlier MGUS recognition are subject to lead-time and selection biases.
• The psychological effects of MGUS diagnosis and ongoing surveillance remain uncertain.
• Whether screening or surveillance reduces end-organ complications or improves survival in asymptomatic individuals remains unanswered.
Why this review matters
MGUS is an asymptomatic condition associated with a risk of progression to MGCS, multiple myeloma, and other lymphoproliferative disorders. Initial evaluation should include SPEP, sIFE, and sFLC, alongside assessment of blood counts, kidney function, and serum calcium, with hematology referral for newly detected M-proteins or unexplained abnormal sFLC ratios. Patients with confirmed low-risk MGUS (M-protein below 15 g/L, IgG isotype, and normal sFLC ratio) may undergo monitoring in primary care, with repeat assessment at 6 months and subsequent follow-up every 2–3 years if stable; however, the benefits of screening and structured follow-up and the optimal monitoring strategy remain uncertain.
Reference:
Khalife R, Lee A, Jimenez-Zepeda VH, Visram A. Diagnosis and management of monoclonal gammopathies. CMAJ. 2026 Nov 1;198(38):E1469-E1475. doi: 10.1503/cmaj.251482.
Bispecific antibodies targeting B-cell maturation antigen in multiple myeloma: current clinical applications, challenges and future directions — Cancer (November 2026)
What is the purpose of the review?
To provide a comprehensive overview of the biological rationale, mechanisms of action, efficacy, safety, and mechanisms of resistance associated with B-cell maturation antigen (BCMA)-targeting bispecific antibodies (bsAbs) in multiple myeloma (MM). It also examines ongoing clinical trials, emerging anti-BCMA bsAbs, combination strategies, their potential use in earlier treatment settings and other diseases, and approaches to monitoring and managing treatment-related toxicities.
Summary
This review evaluated the available clinical and biological evidence on approved anti-BCMA bsAbs (teclistamab, elranatamab, and linvoseltamab) for relapsed/refractory MM, reporting overall response rates (ORRs) of 61%–71%, complete response (CR) rates of 37%–52%, and median progression-free survival (PFS) ranging from 11 months to not reached across the pivotal clinical trials. It examined mechanisms of treatment resistance, including soluble BCMA (sBCMA), BCMA antigen loss or mutation, high tumor burden, extramedullary disease, and T-cell dysfunction, as well as major toxicities, including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), cytopenias, and infections. The review also discussed clinical trials investigating earlier-line treatment, combination regimens, novel agents such as etentamig, and applications in other monoclonal gammopathies and autoimmune conditions.
Key points
Biological rationale and mechanisms of action
• BCMA is expressed on mature B cells and plasma cells and is maintained on multiple myeloma cells.
• BCMA contributes to MM cell survival, proliferation, resistance to apoptosis, immune suppression, angiogenesis, and osteoclast activation.
• Anti-BCMA bsAbs bind BCMA on tumor cells and CD3 on T cells, bringing the cells together and forming an immunologic synapse.
• This interaction activates T cells, resulting in perforin- and granzyme-mediated tumor cell killing, T-cell proliferation, differentiation, and cytokine release.
• Soluble BCMA (sBCMA) may interfere with therapeutic antibody binding by acting as a decoy receptor.
Mechanisms of treatment resistance
• Primary resistance may be associated with:
- Elevated sBCMA levels
- High tumor burden
- Extramedullary disease (EMD)
- An inadequate effector-to-target cell ratio
- Baseline T-cell dysfunction
• Secondary resistance may result from:
- BCMA antigen loss, including biallelic gene deletion.
- Mutations in the BCMA extracellular domain that reduce antibody binding.
- BCMA-independent changes in tumor cell signaling pathways.
• Previous anti-BCMA treatment, International Staging System stage III disease, high tumor burden, and EMD are identified as clinical factors associated with poorer response.
Approved anti-BCMA bispecific antibodies
• Three anti-BCMA bsAbs are approved for relapsed/refractory MM:
- Teclistamab
- Elranatamab
- Linvoseltamab
• Pivotal trials:
- MajesTEC-1: Teclistamab (NCT03145181; NCT04557098)
- MagnetisMM-3: Elranatamab (NCT04649359)
- LINKER-MM1: Linvoseltamab (NCT03761108)
• Across these trials:
- ORR: 61%–71%
- CR rate: 37%–52%
- Median PFS: 11 months to not reached
- Median overall survival (OS): 21–31 months
• Patients achieving CR had higher reported longer-term PFS and response durability.
• Real-world studies generally confirmed clinical trial response rates, although shorter PFS and OS durations were reported.
Efficacy and treatment sequencing
• Post-hoc comparisons with standard-of-care and real-world populations reported improvements in response rates and PFS with teclistamab, elranatamab, and linvoseltamab.
• Responses to anti-BCMA bsAbs following previous anti-BCMA treatment remain possible but may be shorter, particularly after CAR T-cell therapy or belantamab mafodotin.
• Evidence regarding sequential treatment with two different anti-BCMA bsAbs remains limited; one retrospective study reported an ORR of 12.5%.
• Treatment sequencing should consider patient-related factors, disease characteristics, previous therapies, and the potential use of subsequent anti-BCMA treatments.
Treatment-related toxicities and management
• Cytokine release syndrome (CRS): A major early toxicity associated with T-cell activation. Step-up dosing, premedication, monitoring, and treatment with tocilizumab and/or corticosteroids are established management approaches.
• Immune effector cell-associated neurotoxicity syndrome (ICANS): Generally less frequent than CRS. Monitoring includes neurological assessment, with corticosteroids recommended for grade 2 or higher cases.
• Cytopenias: May occur early during treatment. Management includes blood count monitoring, supportive treatments, and dose delays for grade 3 or higher cytopenias.
• Infections: More than half of patients are estimated to experience infections during treatment. Respiratory infections are most common, followed by bacteremia and urinary, skin, soft tissue, and gastrointestinal infections.
• Infection prevention and management include:
- Immunoglobulin replacement
- Antimicrobial prophylaxis
- Recommended vaccinations
- Blood count monitoring and supportive treatment
- Dose-interval adjustments when appropriate.
• Infection incidence has been reported to be higher during the first 3–6 months of treatment in a more recent clinical trial and real-world observations.
Combination therapies and earlier treatment lines
• Ongoing research is evaluating anti-BCMA bsAbs in earlier treatment lines and in combination with other agents, particularly daratumumab and immunomodulatory drugs.
• In the phase 3 MajesTEC-9 study, teclistamab monotherapy demonstrated PFS and OS benefits compared with pomalidomide-bortezomib-dexamethasone or carfilzomib-dexamethasone in patients with 1–3 prior treatment lines.
• In the phase 3 MajesTEC-3 study, teclistamab plus daratumumab reduced the risk of disease progression and death compared with daratumumab-based control regimens.
• In MajesTEC-3, grade 3 or higher infections occurred in 54.1% of patients receiving teclistamab plus daratumumab, compared with 43.4% in the control group.
• Studies in newly diagnosed MM have also evaluated teclistamab- and linvoseltamab-based regimens, reporting high rates of minimal residual disease (MRD) negativity.
Emerging anti-BCMA therapies
• Etentamig is an investigational anti-BCMA bsAb with bivalent BCMA binding and low-affinity CD3 binding.
• In relapsed/refractory MM:
- Monotherapy ORR: 66% across two trials.
- Estimated 12-month PFS: 55%.
- Combination with daratumumab and dexamethasone: ORR of 70%.
- Combination with pomalidomide and dexamethasone: ORR of 81%.
• Other investigational agents include REGN-5459, CM336, and YKST02.
• Trispecific antibodies, including ramantamig, ISB 2001, and BTL-101, are also under investigation.
Applications beyond multiple myeloma
• Anti-BCMA bsAbs are being investigated in:
- High-risk SMM
- MGUS
- Light-chain amyloidosis
- POEMS syndrome
- Cryoglobulinemia
- Systemic sclerosis
- Other autoimmune conditions
• Preliminary clinical results in SMM and light-chain amyloidosis have reported high response rates, although available studies are generally limited by small patient populations and relatively short follow-up.
• In light-chain amyloidosis, reported treatment-related toxicities include CRS and infections, while amyloid-related organ dysfunction has also been associated with fatal events.
• Clinical trials are evaluating investigational agents in additional conditions, including autoimmune bullous disease, immune thrombocytopenia, lupus nephritis, and Waldenström macroglobulinemia.
Strengths
• Provides an overview of the biological rationale and mechanisms of action of anti-BCMA bsAbs.
• Reviews efficacy and safety findings from clinical trials and real-world studies.
• Discusses mechanisms of primary and secondary treatment resistance.
• Examines established toxicity monitoring and management approaches.
• Includes ongoing clinical trials, emerging agents, combination strategies, and potential applications beyond MM.
Limitations
• The pivotal phase 1 and 2 trials of approved anti-BCMA bsAbs were single-arm studies without direct comparisons against standard-of-care treatments.
• Comparisons with standard-of-care populations were based on post-hoc analyses using clinical trial populations or electronic health records.
• Real-world studies reported shorter PFS and OS durations than clinical trials.
• Evidence regarding sequential use of different anti-BCMA bsAbs remains limited.
• Data on several emerging therapies and applications beyond MM are preliminary and based on small patient populations or short follow-up.
• Longer follow-up is needed to confirm the safety and efficacy findings in light-chain amyloidosis and other conditions.
Why this review matters
Anti-BCMA bispecific antibodies, including teclistamab, elranatamab, and linvoseltamab, have demonstrated ORRs of 61%–71% in pivotal clinical trials involving patients with relapsed/refractory MM, with reported CRS, ICANS, cytopenias, and infections requiring established monitoring and management strategies. Ongoing research is evaluating these therapies in earlier treatment lines, combination regimens, and other monoclonal gammopathies and diseases, while investigating novel agents such as etentamig. Further evidence is needed to clarify optimal treatment sequencing, long-term safety, toxicity prevention, and the efficacy of anti-BCMA bsAbs across these additional clinical settings.
Reference:
Manzato E, Cocchetto G, Barbato S, Puppi M, Masci S, Zamagni E. Bispecific antibodies targeting B-cell maturation antigen in multiple myeloma: current clinical applications, challenges and future directions. Cancer. 2026;e70641. doi:10.1002/cncr.70641
Achievement and Persistence of MRD Negativity with Anti-CD38-Based Regimens in Newly Diagnosed Multiple Myeloma: A Systematic Review and Network Meta-Analysis — Cancers (November 2026)
What is the purpose of the review?
To compare frontline treatment strategies for newly diagnosed multiple myeloma (NDMM), particularly anti-CD38 antibody-based quadruplet regimens with and without upfront autologous stem cell transplantation (ASCT), in terms of measurable residual disease (MRD) negativity. The study also aims to evaluate the association between adding an anti-CD38 antibody and sustained MRD (sMRD) negativity in transplant-eligible (TE) and transplant-ineligible (TI) patients.
Summary
This systematic review and network meta-analysis (NMA) included 17 randomized controlled trials involving 6,293 patients with NDMM and compared 13 frontline treatment strategies for achieving MRD negativity. Anti-CD38-based quadruplet regimens, particularly anti-CD38–carfilzomib-lenalidomide-dexamethasone (KRd), anti-CD38–bortezomib-lenalidomide-dexamethasone (VRd) followed by ASCT, and anti-CD38–KRd followed by ASCT, had the highest treatment rankings, with no statistically significant differences among these strategies. Adding an anti-CD38 antibody was associated with approximately threefold higher odds of sustained MRD negativity (maintained for at least 12 months) in both TE and TI populations; however, the available evidence did not establish whether upfront ASCT provides additional benefit when combined with anti-CD38-based quadruplet regimens.
Key points
Study design and population
• Systematic review and frequentist random-effects network meta-analysis of randomized controlled trials.
• 17 randomized trials involving 6,293 patients with newly diagnosed multiple myeloma.
• 13 frontline treatment strategies were included in the treatment network.
• Both transplant-eligible and transplant-ineligible populations were evaluated.
• The literature search covered records published up to July 31, 2026.
• The primary outcome was MRD negativity; the secondary outcome was sustained MRD negativity, defined as MRD negativity maintained for at least 12 months at a sensitivity threshold of 10⁻⁵.
Main findings: MRD negativity
• Anti-CD38-based quadruplet regimens had the highest probability of achieving MRD negativity among the evaluated treatment strategies.
• No statistically significant differences were observed among the three highest-ranked strategies.
• No comparison between a treatment strategy with ASCT and its corresponding strategy without ASCT reached statistical significance.
• For VRd + ASCT versus VRd alone, the OR was 1.72 (95% CI 0.95–3.10).
• The confidence interval included 1, indicating that this comparison did not demonstrate a statistically significant difference.
Important statistical distinction
The absence of statistically significant differences does not establish that the treatment strategies are equivalent, or that ASCT provides no additional benefit.
Main findings: Sustained MRD negativity
• Sustained MRD negativity was defined as MRD negativity maintained for at least 12 months at a threshold of 10⁻⁵.
• Adding an anti-CD38 antibody to the same treatment backbone was associated with higher odds of sustained MRD negativity in both populations.
• The test for subgroup differences showed no evidence that the association differed between the two populations (p for interaction = 0.88).
• A network meta-analysis of sustained MRD negativity was not feasible because the available data did not connect transplant-based, carfilzomib-based, and non-transplant treatment strategies.
• Consequently, sustained MRD outcomes could not be directly compared between quadruplet strategies with and without ASCT.
Additional Clinical Findings: MIDAS Trial
The phase III MIDAS (IFM 2020-02) trial evaluated the contribution of ASCT in patients receiving isatuximab–KRd (Isa-KRd).
• Among 485 patients who achieved MRD negativity at 10⁻⁵ after induction, patients were randomized to:
- ASCT followed by two cycles of Isa-KRd
- Six additional cycles of Isa-KRd without ASCT
• MRD negativity at 10⁻⁶ after consolidation was:
- 86% in the ASCT group.
- 84% in the non-ASCT group.
- The difference was not statistically significant (p = 0.64)
• Among MRD-positive patients, tandem ASCT did not significantly improve MRD negativity compared with single ASCT (32% versus 40%; p = 0.31).
• The study authors noted that neither the MIDAS trial nor the present NMA could establish whether ASCT improves sustained MRD negativity or long-term outcomes.
• Progression-free survival (PFS) data from MIDAS were immature at the time of the reported analysis.
Strengths
The following methodological strengths are supported by the study's reported methods:
• Comprehensive literature searches across PubMed/MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials, including major international hematology and oncology conference proceedings.
• Independent study screening and data extraction by two investigators, with disagreements resolved through discussion and consensus.
• Inclusion of randomized controlled trials comparing multiple frontline treatment strategies.
• Assessment of risk of bias using the Cochrane Risk of Bias tool.
• Evaluation of confidence in the network meta-analysis using the CINeMA framework.
• Multiple sensitivity analyses to assess the consistency and robustness of treatment rankings.
• Assessment of global and local inconsistency within the treatment network.
Limitations
• Most treatment comparisons were indirect, and the validity of network estimates depended on the transitivity assumption.
• Differences between TE and TI populations in age, fitness, comorbidities, cytogenetic risk, and treatment intensity may have affected the comparability of indirect treatment estimates.
• MRD assessments varied across trials in methodology, sensitivity thresholds, assessment timing, analysis populations, and outcome definitions.
• Sustained MRD data were insufficient to compare quadruplet strategies with and without ASCT.
• Several treatment strategies were informed by only one trial, limiting the statistical power to detect inconsistency.
• Data from COBRA, ADVANCE, and AGMT-MM04 were obtained from conference abstracts; AGMT-MM04 reported an interim per-protocol analysis.
• Publication bias could not be formally assessed using comparison-adjusted funnel plots because no treatment comparison was informed by more than three trials.
• Daratumumab and isatuximab were grouped into a common anti-CD38 category in the primary analysis, assuming a class effect. Their individual comparative effects could not be established through indirect comparisons.
• PFS and overall survival (OS) were not analyzed in the present NMA.
Why this review matters
Anti-CD38-based quadruplet regimens had the highest probability of achieving MRD negativity in patients with newly diagnosed multiple myeloma, while adding an anti-CD38 antibody was associated with approximately threefold higher odds of sustained MRD negativity in both transplant-eligible and transplant-ineligible populations. However, the three highest-ranked strategies did not demonstrate statistically significant differences, and available evidence did not establish an additional benefit of upfront ASCT when combined with quadruplet regimens. Whether ASCT improves the persistence of MRD negativity or long-term outcomes in this treatment setting remains uncertain and requires direct randomized comparisons incorporating standardized MRD assessments, sustained MRD outcomes, and long-term follow-up.
Reference:
Caridà, G., Scalise, L., Mosca, A., De Fazio, L., Costa, M., Molica, M., & Rossi, M. (2026). Achievement and Persistence of MRD Negativity with Anti-CD38-Based Regimens in Newly Diagnosed Multiple Myeloma: A Systematic Review and Network Meta-Analysis. Cancers, 18(21), 3573. https://doi.org/10.3390/cancers18213573
Carfilzomib in Contemporary Multiple Myeloma: Contextualising Efficacy, Toxicity, and Treatment Sequencing — Hemato (November 2026)
What is the purpose of the review?
To evaluate the clinical evidence on the use of carfilzomib in multiple myeloma across newly diagnosed disease, maintenance, and relapsed or refractory disease. It examines treatment efficacy, comparative outcomes, safety, dosing schedules, resistance mechanisms, and treatment sequencing to clarify which patient populations may benefit from specific carfilzomib-containing regimens.
Summary
This critical narrative review integrates evidence from randomized clinical trials, selected translational and observational studies, and clinical guidance, with source verification through October 16, 2026, to assess the role of carfilzomib in multiple myeloma. In newly diagnosed disease, ENDURANCE and CLARION did not demonstrate progression-free survival (PFS) superiority over bortezomib-based regimens, whereas in relapsed or refractory disease, ASPIRE, ENDEAVOR, CANDOR, and IKEMA demonstrated PFS benefits with specific carfilzomib-containing combinations; however, CANDOR and IKEMA did not establish an overall survival (OS) advantage. The review also evaluates cardiovascular, renal, and infectious risks, treatment schedules, and emerging evidence from SUCCESSOR-2, concluding that optimal treatment sequencing remains undefined and that clinical benefit depends on prior treatment exposure, disease status, regimen, and treatment tolerability.
Key points
Efficacy in NDMM
• ENDURANCE: Carfilzomib–lenalidomide–dexamethasone (KRd) did not demonstrate PFS superiority over bortezomib–lenalidomide–dexamethasone (VRd) in patients without immediate transplant intent.
• CLARION: Carfilzomib–melphalan–prednisone (KMP) did not demonstrate PFS superiority over bortezomib–melphalan–prednisone (VMP) in transplant-ineligible patients. KMP was associated with greater cardiac and renal toxicity and less peripheral neuropathy.
• FORTE and ATLAS: Evaluated carfilzomib-containing induction and maintenance strategies, respectively. ATLAS demonstrated longer PFS with risk- and measurable residual disease (MRD)-adapted KRd maintenance compared with lenalidomide alone.
• IsKia: Adding isatuximab to KRd increased post-consolidation MRD negativity at 10−510−5 compared with KRd alone (77% versus 67%; OR 1.67, 95% CI 1.00–2.80; p = 0.049). Survival data remained immature in the reported analysis.
Efficacy in RRMM
• ASPIRE and ENDEAVOR: Established PFS and OS benefits for carfilzomib-containing regimens compared with lenalidomide–dexamethasone (Rd) and bortezomib–dexamethasone (Vd), respectively.
• ARROW: Weekly carfilzomib at 70 mg/m² with dexamethasone improved PFS compared with twice-weekly carfilzomib at 27 mg/m² with dexamethasone.
• CANDOR: Daratumumab–carfilzomib–dexamethasone (Dara-Kd) improved PFS compared with Kd. The final OS analysis did not establish an OS advantage.
• IKEMA: Isatuximab–carfilzomib–dexamethasone (Isa-Kd) improved PFS compared with Kd. At a median follow-up of 56.61 months, the OS hazard ratio was 0.855 (95% CI 0.608–1.202), without a detected OS difference.
• SUCCESSOR-2: Mezigdomide–carfilzomib–dexamethasone (Mezi-Kd) improved PFS compared with the tested Kd control in patients previously exposed to lenalidomide and anti-CD38 therapy. Mezi-Kd was associated with increased severe neutropenia and infection. Differences in carfilzomib schedules between treatment arms limit attribution of the benefit to mezigdomide alone.
Treatment scheduling and delivery
• Carfilzomib regimens differ in dose, infusion duration, frequency, treatment duration, and combination partners.
• Different dosing schedules, including K27, K36, K56, and K70, should not be considered interchangeable.
• Observational evidence has not established non-inferiority or a universally optimal weekly dosing schedule.
• Treatment burden includes infusion attendance, laboratory monitoring, hospitalization, treatment interruptions, and cumulative exposure.
Safety and treatment-related risks
• Cardiovascular toxicity: Reported adverse events include hypertension, ischemia, arrhythmias, and heart failure with preserved or reduced ejection fraction.
• Renal toxicity: Reported complications include acute kidney injury, albuminuria, and thrombotic microangiopathy (TMA).
• Infectious complications: Infection risk and cytopenias are relevant, particularly with combination regimens containing mezigdomide or anti-CD38 antibodies.
• Baseline cardiovascular and renal assessment, blood pressure monitoring, and evaluation of new symptoms are important components of treatment surveillance.
• The prescribing information recommends withholding carfilzomib for grade 3–4 cardiac adverse reactions while the event is evaluated and stopping treatment when TMA is suspected.
Treatment sequencing and emerging evidence
• The evidence supporting Dara-Kd and Isa-Kd applies most directly to patients who are naïve to both carfilzomib and anti-CD38 therapy.
• Neither CANDOR nor IKEMA establishes the benefit of routine anti-CD38 antibody retreatment in patients with anti-CD38-refractory disease.
• SUCCESSOR-2 provides evidence for Mezi-Kd in patients previously exposed to lenalidomide and anti-CD38 therapy, although regulatory availability and its position relative to T-cell-directed therapies remain unresolved.
• Evidence for carfilzomib after B-cell maturation antigen (BCMA)-directed therapy remains investigational.
• Current evidence does not establish an optimal treatment sequence or demonstrate that carfilzomib preserves all subsequent treatment options.
Strengths
• Integrates randomized trials, selected translational and observational studies, clinical guidance, and targeted source verification.
• Prioritizes primary publications, prespecified updates, and publisher correction records.
• Verifies numerical findings against primary publications or indexed abstracts.
• Distinguishes treatment phases, trial designs, treatment exposure, dosing schedules, and follow-up periods.
• Evaluates comparative efficacy and safety while distinguishing PFS, OS, and MRD outcomes.
Limitations
• The literature search was selective and primarily PubMed-centred.
• Screening and data extraction were not independently duplicated.
• Record-level exclusions were not logged.
• No review protocol was registered.
• No formal risk-of-bias assessment or pooled effect estimate was calculated.
• Historical comparator regimens and restricted eligibility criteria limit applicability to contemporary treatment settings.
• Differences in follow-up, safety reporting, and subsequent therapies complicate cross-trial comparisons and OS interpretation.
• Targeted searches may have missed relevant publications.
• Selected safety outcomes were reported rather than an exhaustive inventory.
Why this review matters
Carfilzomib-containing regimens demonstrate clinical benefit in specific multiple myeloma treatment settings, particularly Dara-Kd and Isa-Kd in relapsed or refractory patients who are naïve to carfilzomib and anti-CD38 therapy, with established PFS benefits but no demonstrated OS advantage in the reported analyses. In newly diagnosed disease, ENDURANCE and CLARION did not demonstrate PFS superiority over bortezomib-based comparators, while SUCCESSOR-2 provides emerging evidence for Mezi-Kd in patients previously exposed to lenalidomide and anti-CD38 therapy, with increased severe neutropenia and infection. Treatment selection remains dependent on prior therapy, cardiovascular and renal status, treatment tolerability, and access, while optimal sequencing and direct comparisons of contemporary regimens remain unresolved.
Reference:
Hjazi, A. M., Matta, A. R. H., Meshal Almalki, M., Mohamad Safwan Almassri, A., & Bashir Ibrahim Elbashir, I. (2026). Carfilzomib in Contemporary Multiple Myeloma: Contextualising Efficacy, Toxicity, and Treatment Sequencing. Hemato, 7(4), 43. https://doi.org/10.3390/hemato7040043
Research
Clinical and Laboratory Factors Associated with Serious Infections in Multiple Myeloma: A Real-World Study — Current Oncology (October 2026)
What is the purpose of the study?
To evaluate clinical, disease-related, treatment-related, and laboratory factors associated with serious infections requiring hospitalization in patients with multiple myeloma (MM). The study also investigates whether baseline neutrophil-to-lymphocyte ratio (NLR) was associated with subsequent serious infections independently of other clinical factors.
Summary
This retrospective multicenter cohort study included 104 patients with MM and evaluated clinical and laboratory factors associated with serious infections, defined as infectious episodes requiring hospitalization, throughout follow-up, including during second-line and subsequent therapies. Serious infections occurred in 39 patients (37.5%); dialysis requirement at diagnosis (adjusted odds ratio [OR] 8.26, 95% confidence interval [CI] 1.81–37.68; p = 0.006) and failure to achieve treatment response (adjusted OR 16.77, 95% CI 4.37–64.31; p < 0.001) were independently associated with serious infection. Baseline NLR did not differ significantly between patients with and without serious infection and was not independently associated with the outcome in multivariable analysis; hypogammaglobulinemia and intravenous immunoglobulin (IVIG) administration were more frequent among patients with serious infection in univariate analyses.
Key points
• Study design and population: Retrospective multicenter cohort study involving 104 patients with multiple myeloma.
• Primary outcome: Serious infection, defined as an infectious episode requiring hospitalization. Events occurring throughout follow-up, including during second-line and subsequent therapies, were recorded.
• Incidence: Serious infections occurred in 39 of 104 patients (37.5%).
Factors independently associated with serious infection
• Dialysis requirement at diagnosis: Adjusted OR 8.26 (95% CI 1.81–37.68; p = 0.006).
• Failure to achieve treatment response: Adjusted OR 16.77 (95% CI 4.37–64.31; p < 0.001).
Baseline neutrophil-to-lymphocyte ratio (NLR)
• Baseline NLR did not differ significantly between patients with and without serious infection.
• NLR was not independently associated with serious infection after adjustment for age, International Staging System (ISS) stage, dialysis requirement at diagnosis, and treatment response.
Other factors associated with serious infection in univariate analyses
• Hypogammaglobulinemia: 48.7% of patients with serious infection versus 29.2% without serious infection (p = 0.046).
• IVIG administration: 76.9% of patients with serious infection versus 46.2% without serious infection (p = 0.002).
• These associations do not establish causation. The authors caution that the association between IVIG administration and serious infection may reflect confounding by indication and reverse causality.
Strengths
• Evaluation of serious infections and IVIG administration in a real-world multiple myeloma cohort.
• Inclusion of demographic, disease-related, treatment-related, and laboratory variables.
• Use of multivariable logistic regression to assess independent associations after adjustment for potential confounding factors.
• Consistency of the main findings in a Firth penalized likelihood sensitivity analysis, supporting the robustness of the primary multivariable results despite the relatively modest number of serious infection events.
Limitations
• Retrospective multicenter design: Potential selection and information bias; causal relationships cannot be established.
• Sample size: The relatively modest cohort size may have limited statistical power to detect weaker associations, particularly those involving NLR.
• NLR assessment: Measured only at diagnosis, without evaluation of changes in inflammatory or immune status during treatment.
• Timing of infection: The exact interval from diagnosis or treatment initiation to the first serious infection was not collected as a separate analytical variable.
• Treatment-related data: Although initial treatment regimens were available and predominantly VCD-based (bortezomib, cyclophosphamide, and dexamethasone), subsequent treatment exposures were not systematically available. The specific treatment regimen and line of therapy at the time of each serious infection were also not systematically captured. Consequently, infection risks associated with newer approaches, including quadruplet regimens, BCMA-directed bispecific antibodies, and CAR-T-cell therapy, could not be specifically evaluated.
• IVIG administration: Based on physician judgment and institutional clinical practice rather than predefined standardized criteria, limiting causal interpretation of its association with serious infection.
• Immune biomarkers: Quantitative serum IgG levels were unavailable; hypogammaglobulinemia was recorded categorically using a serum IgG threshold of less than 5 g/L. CD4+ T-cell counts and ferritin levels were not systematically available.
• Other clinical outcomes and variables: Recurrent serious infections, intensive care unit admissions, renal recovery following dialysis, and infection-attributable mortality could not be reliably assessed.
Why this study matters
In this retrospective multicenter cohort of 104 patients with multiple myeloma, serious infections requiring hospitalization occurred in 37.5% of patients. Dialysis requirement at diagnosis and failure to achieve treatment response were independently associated with serious infection, whereas baseline NLR showed neither a significant between-group difference nor an independent association in multivariable analysis. Prospective multicenter studies are needed to validate these findings, evaluate longitudinal clinical and immune parameters, and develop standardized infection-risk assessment and prevention strategies, including appropriate patient selection for IVIG therapy.
Reference:
Odabaşı Giden, A., Şahin, O., & Ozatli, D. (2026). Clinical and Laboratory Factors Associated with Serious Infections in Multiple Myeloma: A Real-World Study. Current Oncology, 33(10), 615. https://doi.org/10.3390/curroncol33100615
Ki-67 Proliferation Index Improves the Prognostic Stratification Accuracy of International Staging System in Newly Diagnosed Multiple Myeloma — Cancers (October 2026)
What is the purpose of the study?
To investigate the clinical characteristics and prognostic significance of the Ki-67 proliferation index in patients with newly diagnosed multiple myeloma (NDMM). The study also aims to improve prognostic risk stratification by combining the Ki-67 proliferation index with the International Staging System (ISS).
Summary
This single-center, retrospective study analyzed clinical data from 307 patients with NDMM treated at the Second Hospital of Shanxi Medical University between January 2015 and December 2023. Patients with a Ki-67 proliferation index greater than 10% had significantly shorter median progression-free survival (PFS) and overall survival (OS) than those with an index of 10% or lower, and Ki-67 was identified as an independent prognostic factor for both outcomes. A three-group risk-stratification model combining Ki-67 with ISS stage showed significant differences in PFS and OS across groups and identified differences in risk among patients within the conventional ISS stages.
Key points
• Study design and population: Retrospective analysis of 307 patients with newly diagnosed multiple myeloma (NDMM) at a single medical center, from January 2015 to December 2023.
• Ki-67 distribution: 199 patients (64.82%) had a Ki-67 proliferation index of 10% or lower; the remaining 108 patients (35.18%) had an index greater than 10%.
• Progression-free survival (PFS):
- Ki-67 ≤ 10%: median PFS was 45.52 months (95% CI: 39.40–51.66).
- Ki-67 > 10%: median PFS was 25.81 months (95% CI: 20.61–31.00).
- The difference was statistically significant (p < 0.001).
• Overall survival (OS):
- Ki-67 ≤ 10%: median OS was 61.61 months (95% CI: 54.48–68.74)
- Ki-67 > 10%: median OS was 34.78 months (95% CI: 28.89–40.66).
- The difference was statistically significant (p < 0.001).
• Independent prognostic factor: Multivariable Cox proportional hazards regression identified Ki-67 as an independent prognostic factor for PFS (HR: 1.227; 95% CI: 1.097–1.743; p = 0.043) and OS (HR: 1.192; 95% CI: 1.169–1.847; p = 0.048).
• Combined ISS–Ki-67 risk stratification: Patients were classified into three groups:
- Group I: 103 patients (33.55%).
- Group II: 138 patients (44.95%).
- Group III: 66 patients (21.50%).
• Survival across the combined risk groups:
- Median PFS was 49.74, 35.00, and 17.00 months in Groups I, II, and III, respectively (p = 0.011).
- Median OS was 71.38, 59.51, and 26.64 months, respectively (p < 0.001).
• Clinical relevance reported by the authors: The combined model distinguished patients with different prognoses within conventional ISS stages, including high-risk patients in ISS stage I and relatively low-risk patients in ISS stage III.
Strengths
The model uses routine clinical risk factors and incorporates Ki-67 into the established ISS framework. The authors also describe its potential applicability in clinical settings where complete cytogenetic data is unavailable.
Limitations
• The retrospective, single-center study design is subject to selection bias
• No independent, multicenter validation cohort was included.
• The Ki-67 measurement method could not reliably distinguish plasma cells from non-plasma-cell populations, and interference from other cell types could not be fully excluded.
• The authors state that the combined risk-stratification model requires validation in independent real-world cohorts.
Why this study matters
In this cohort of 307 patients with NDMM, a Ki-67 proliferation index greater than 10% was associated with significantly shorter PFS and OS and was identified as an independent prognostic factor for both outcomes. Combining Ki-67 with ISS staging produced three risk groups with significantly different survival outcomes. However, the model requires further validation in independent cohorts, and the authors acknowledge limitations related to the Ki-67 measurement method and the retrospective, single-center study design.
Reference:
Qin, X., Zhao, J., Bai, Q., Qiu, Q., Li, S., Zhang, Y., Zhang, L., & Ma, Y. (2026). Ki-67 Proliferation Index Improves the Prognostic Stratification Accuracy of International Staging System in Newly Diagnosed Multiple Myeloma. Cancers, 18(20), 3312. https://doi.org/10.3390/cancers18203312
Rapid peak cilta-cel expansion is associated with delayed neurotoxicity in multiple myeloma — Blood (October 2026)
What is the purpose of the study?
To evaluate the relationships between chimeric antigen receptor (CAR) T-cell expansion, treatment efficacy, and treatment-related toxicity in patients with relapsed/refractory (R/R) multiple myeloma (MM) treated with idecabtagene vicleucel (ide-cel) or ciltacabtagene autoleucel (cilta-cel). The study also investigates whether absolute lymphocyte count (ALC) could serve as a surrogate marker of CAR T-cell expansion and help identify patients at increased risk of delayed neurotoxicities (DNTs).
Summary
This retrospective, multicenter study evaluated CAR T-cell kinetics using flow cytometry (FC) in 90 patients and assessed ALC as a surrogate marker in a separate cohort of 532 patients who received ide-cel or cilta-cel between April 2021 and January 2025. Median CAR T-cell expansion was greater with cilta-cel than with ide-cel (106 vs 49 cells/μL); peak expansion was associated with clinical response in the ide-cel cohort, whereas greater expansion in the cilta-cel cohort was associated with increased DNT risk, particularly parkinsonism. In the 532-patient cohort, higher peak ALC was associated with DNTs, and ALC thresholds of ≥3 × 10³/μL or ≥2.5 × 10³/μL accompanied by an increase of at least twofold were associated with elevated DNT risk, with 81% sensitivity and 59% specificity; these thresholds require prospective validation before their clinical utility can be established.
Key points
• Study design: Retrospective, multicenter study of patients with R/R MM who received commercial B-cell maturation antigen (BCMA)-directed CAR T-cell therapy between April 2021 and January 2025.
• Study populations:
- FC cohort: 90 patients, including 54 treated with cilta-cel and 36 with ide-cel.
- ALC cohort: 532 patients from three centers, including 256 treated with cilta-cel and 276 with ide-cel.
• CAR T-cell expansion: Median expansion was higher with cilta-cel than with ide-cel (106 vs 49 cells/μL).
• Association with clinical response: Peak CAR T-cell expansion was associated with clinical response in the ide-cel cohort but not in the cilta-cel cohort. These findings describe associations and do not establish that greater expansion caused a clinical response.
• Association with toxicity: In the cilta-cel cohort, greater CAR T-cell expansion was associated with increased DNT risk. Median peak expansion was 1,009 cells/μL among patients who developed DNTs versus 96 cells/μL among those who did not.
• ALC as a surrogate marker: Peak ALC showed a positive correlation with CAR T-cell expansion. Higher peak ALC was associated with DNTs, particularly parkinsonism, following cilta-cel treatment.
• ALC thresholds associated with elevated DNT risk:
- Peak ALC ≥3 × 10³/μL.
- ALC ≥2.5 × 10³/μL accompanied by an increase of at least twofold.
- These thresholds had 81% sensitivity and 59% specificity for identifying DNT risk.
- These values are risk-stratification thresholds, not definitive diagnostic criteria; they do not establish that an individual patient will or will not develop DNTs.
• Clinical relevance: ALC is a routinely available laboratory measure that may help identify patients at increased risk of DNTs during the early postinfusion period. Prospective studies are needed to validate the thresholds and assess whether ALC-guided interventions reduce toxicity.
Strengths
• Used a standardized flow cytometry platform to evaluate and compare CAR T-cell expansion with ide-cel and cilta-cel.
• Assessment of ALC as a practical, routinely available surrogate marker in a large, three-center cohort.
• Evaluation of relationships between CAR T-cell kinetics, clinical response, and treatment-related toxicities.
Limitations
• Retrospective study design.
• Modest sample size for the flow cytometry cohort.
• Variability in sampling frequency.
• Bone marrow plasmacytosis, a known predictor of DNTs with cilta-cel in clinical trials, was not uniformly captured in routine clinical practice.
• Data on extramedullary disease (EMD) and certain additional tumor-burden biomarkers were unavailable in the study cohort.
• Prospective studies are needed to validate the findings and further investigate factors associated with CAR T-cell expansion, efficacy, and toxicity.
Why this study matters
Cilta-cel was associated with greater CAR T-cell expansion than ide-cel, and the relationships between expansion, clinical response, and toxicity differed between the treatment cohorts. Higher peak ALC was associated with DNTs, particularly parkinsonism following cilta-cel, and the identified ALC thresholds had 81% sensitivity and 59% specificity for DNT risk. Prospective validation is required to establish the predictive performance and clinical utility of these thresholds and determine whether interventions guided by ALC monitoring can reduce DNT incidence or severity.
Reference:
Hitomi Hosoya, Arash Velayati, Danai Dima, Alexandria Jensen, Andrew J. Portuguese, Vanna Hovanky, Lekha Mikkilineni, Lauren C. Peres, Ariel Grajales-Cruz, Sylvester Homsy, Masooma Rana, Juancarlos Cancilla, Sunita Patil, Bita Sahaf, Theresa Latchford, Ciara Freeman, Brian Scott, Kun Wei Song, Omar Castaneda Puglianini, Humza Khan, Saurabh Dahiya, Frederick Locke, Crystal Mackall, David Miklos, Rahul Banerjee, Doris Hansen, Melissa Alsina, Surbhi Sidana; Rapid peak cilta-cel expansion is associated with delayed neurotoxicity in multiple myeloma. Blood 2026; 148 (16): 1961–1972. doi: https://doi.org/10.1182/blood.2025032844
Infectious Complications and Toxicities of the Teclistamab Plus Daratumumab Combination in Relapsed or Refractory Multiple Myeloma: A Disproportionality and Drug–Interaction Analysis of the FDA Adverse Event Reporting System — Cancers (October 2026)
What is the purpose of the study?
To evaluate whether teclistamab plus daratumumab (Tec-Dara), a combination approved in March 2026 for relapsed or refractory multiple myeloma, was associated with higher-than-expected reporting of adverse events compared with reporting for either drug alone. The analysis focuses on respiratory infections and other toxicities using data from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).
Summary
This pharmacovigilance study analyzed FAERS reports from the fourth quarter of 2022 through the fourth quarter of 2025, comparing 353 reports listing both teclistamab and daratumumab with 2,774 teclistamab-only reports and 19,230 daratumumab-only reports; all combination reports preceded the combination's March 2026 approval. Pneumonia (Ω = 1.50; 95% CI, 1.06–2.12) and influenza (Ω = 2.63; 95% CI, 1.20–5.77) had higher-than-expected reporting, where Ω measures deviation from the expected adverse-event reporting pattern under the study's statistical framework and does not represent the relative risk of developing these infections. Cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and cytopenias were reported less often than expected; these findings do not establish lower underlying risks, and the pneumonia signal lost statistical significance in two sensitivity analyses addressing potential confounding. Because the study used pre-approval safety reports, it cannot determine whether these reporting patterns persist in post-approval routine clinical practice or under the prescribing information recommended infection-prevention measures.
Key points
• Study design: Retrospective pharmacovigilance analysis using the FDA Adverse Event Reporting System (FAERS).
• Study period: Q4 2022–Q4 2025, before the combination's approval in March 2026.
• Treatment: Teclistamab plus daratumumab (Tec-Dara) for relapsed or refractory multiple myeloma.
• Reports analyzed:
- Tec-Dara: 353
- Teclistamab alone: 2,774
- Daratumumab alone: 19,230
Principal findings
• Pneumonia: Higher-than-expected reporting (Ω = 1.50; 95% CI, 1.06–2.12; 57 reports). The Ω value is an interaction measure of adverse-event reporting, not a relative risk or incidence estimate.
• Influenza: Higher-than-expected reporting (Ω = 2.63; 95% CI, 1.20–5.77; 9 reports). The small number of reports limits the strength of this signal.
• CRS, ICANS, and cytopenias: Reported less often than expected. These results describe reporting patterns and do not demonstrate that the combination reduces the incidence of these toxicities or that daratumumab has a protective effect.
• Bone marrow failure: The signal was based on 13 combination reports and 4 teclistamab-only reports. The authors considered it statistically fragile and hypothesis-generating, and stated that it should not guide clinical practice before confirmation.
• Sensitivity analyses: The pneumonia estimate was no longer statistically significant after excluding reports that co-listed immunomodulatory drugs or proteasome inhibitors and when the daratumumab comparator was restricted to relapsed-disease regimens.
• Clinical recommendation: The authors recommend same-day evaluation of any new respiratory symptom or fever in patients receiving Tec-Dara, including multiplex respiratory pathogen testing and chest imaging, alongside guideline-recommended infection-prevention measures.
Strengths
• Used a large FAERS background dataset containing more than 4.6 million safety reports.
• Application of a formal drug–drug interaction framework to quantify adverse-event reporting beyond that expected from either agent alone.
• Sensitivity analyses addressing calendar period, sparse event counts, comparator selection, confounding, and alternative statistical scales.
• Assessment of related adverse-event terms and positive controls to examine the robustness of selected signals.
Limitations
• FAERS reports are voluntary and incomplete and may be affected by reporting bias.
• The database lacks exposure denominators, preventing estimation of actual adverse-event incidence or relative risk.
• The combination cohort was small, with 353 reports.
• Differences in treatment populations, disease severity, prior therapies, concomitant medications, and reporting channels may have confounded the findings.
• Co-reporting of both drugs does not establish concurrent administration, and duplicate reports may remain despite deduplication.
• All combination reports preceded approval in March 2026, limiting assessment of post-approval reporting in routine clinical practice.
• The database lacks sufficient patient-level clinical information to fully adjust for potential confounders, including treatment line, disease burden, immunoglobulin levels, and infection-prevention measures.
• Interaction classifications can vary with the statistical scale used.
• The study did not include efficacy outcomes and therefore could not assess the overall benefit–risk balance of the combination.
• Spontaneous reporting data cannot establish the timing or causality of adverse events.
Why this study matters
The study identified higher-than-expected reporting of pneumonia and influenza with teclistamab plus daratumumab, while CRS, ICANS, and cytopenias were not reported more often than expected. These findings describe adverse-event reporting patterns rather than actual clinical incidence or causality; the pneumonia signal lost statistical significance in two sensitivity analyses addressing potential confounding, and the pre-approval data cannot establish whether the signals persist under routine post-approval treatment conditions. The authors recommend same-day evaluation of any new respiratory symptom or fever, including multiplex respiratory pathogen testing and chest imaging, alongside guideline-recommended immunoglobulin replacement when indicated, antimicrobial prophylaxis, and vaccination; prospective studies with defined exposure denominators are needed to validate the respiratory infection and bone marrow failure signals.
Reference:
Awadallah, C., Irfan, S., Abdallah, A.-O., & Bilal Abid, M. (2026). Infectious Complications and Toxicities of the Teclistamab Plus Daratumumab Combination in Relapsed or Refractory Multiple Myeloma: A Disproportionality and Drug–Interaction Analysis of the FDA Adverse Event Reporting System. Cancers, 18(20), 3388. https://doi.org/10.3390/cancers18203388
Temporal trends in infectious risk among multiple myeloma patients treated with daratumumab: A meta-analysis — British Journal of Haematology (October 2026)
What is the purpose of the study?
To characterize the timing, frequency, severity, and recurrence of infections in patients with multiple myeloma (MM) receiving daratumumab-containing regimens compared with non-daratumumab-containing regimens. The study also evaluates factors associated with infection risk and the use of antimicrobial prophylaxis and immunoglobulin replacement therapy over two years.
Summary
This individual patient-level meta-analysis included 2,989 patients from six randomized clinical trials comparing daratumumab-containing and non-daratumumab-containing regimens in patients with newly diagnosed multiple myeloma (NDMM) or relapsed/refractory multiple myeloma (RRMM). Over two years, infections of any grade occurred in 79% of daratumumab-treated patients versus 61% of controls, while grade ≥3 infections occurred in 29% versus 20%, respectively; infection risk was highest during the first three months, when adjusted analyses showed higher odds of any-grade, respiratory, and grade ≥3 infections with daratumumab-containing regimens. Recurrent infections were more frequent in the daratumumab group, while secondary intravenous immunoglobulin (IVIG) prophylaxis after a first documented grade ≥3 respiratory infection was reported in 18.5% of daratumumab-treated patients who experienced such an infection.
Key points
• Study design and population: Individual patient-level meta-analysis of six randomized clinical trials involving 2,989 patients: 1,500 received daratumumab-containing regimens and 1,489 received non-daratumumab-containing regimens. Infection outcomes were assessed over two years.
• Overall infection rates: Infections of any grade occurred in 79% of daratumumab-treated patients versus 61% of controls. Grade ≥3 infections occurred in 29% versus 20%, respectively.
• Timing of infection risk: During the first three months, any-grade infections occurred in 42% of daratumumab-treated patients versus 36% of controls (p = 0.001). Grade ≥3 infections occurred in 13% versus 10%, respectively (p < 0.001). Infection risk subsequently plateaued, although any-grade infection risk remained higher in the daratumumab group.
• Adjusted infection risk by three months: Daratumumab-containing regimens were associated with:
- Any-grade infection: Odds ratio (OR) 1.31 (95% confidence interval [CI] 1.09–1.57).
- Respiratory infection: OR 1.38 (95% CI 1.11–1.71), as reported in the study abstract
- Grade ≥3 infection: OR 1.47 (95% CI 1.08–2.00).
The detailed results also report an OR of 1.37 (95% CI 1.11–1.71) for grade ≥1 respiratory infection in a sensitivity analysis. These estimates are retained with their respective reporting contexts.
• Long-term infection incidence: Over two years, the adjusted incidence rate ratio for grade ≥1 infections was 1.60 (95% CI 1.47–1.73) for daratumumab-containing versus non-daratumumab-containing regimens.
• Recurrent infections: Multiple grade 1–2 infections occurred in 33% of daratumumab-treated patients versus 22% of controls. Multiple grade ≥3 infections occurred in 11% versus 7%, respectively.
• Infection types: Respiratory infections predominated in both groups. Among patients with any infection, 71% of daratumumab-treated patients and 66% of controls had upper respiratory infections. Pneumonia accounted for 42% and 37% of grade ≥3 infections, respectively.
• Preventive measures: Antimicrobial prophylaxis rates were comparable between groups: antibiotic prophylaxis, 47% versus 43%; Pneumocystis jirovecii pneumonia (PJP) prophylaxis, 31.9% versus 28.6%; and fluoroquinolone prophylaxis, 12% versus 11%. Respiratory vaccine use recorded in the study was below 2% in both groups. Among daratumumab-treated patients with grade ≥3 respiratory infections, 18.5% (55 of 297) received secondary IVIG prophylaxis after the first documented respiratory infection.
Strengths
The authors characterize this as the first and largest patient-level meta-analysis to examine infection risk over time in patients receiving modern multiple myeloma therapies, including anti-CD38 monoclonal antibodies. The analysis included nearly 3,000 patients from six randomized trials and longitudinal follow-up through two years, enabling assessment of infection timing and recurrence.
Limitations
• Quarterly infection percentages were based on patient counts rather than person-time, potentially underestimating risk in quarters with greater early censoring or loss to follow-up.
• Most infections lack specified pathogens, limiting pathogen-specific analysis.
• Antimicrobial prophylaxis duration could not be assessed because treatment stop dates were inconsistently documented.
• Respiratory vaccine use may have been underestimated because data capture was limited to study initiation.
• Immunoglobulin measurements were available only at baseline, preventing assessment of IgG levels when IVIG was initiated.
• The analysis could not determine the effects of infections on treatment delays, dose reductions, or discontinuation.
• The study included clinical trial populations that may not represent frailer or more comorbid patients in routine clinical practice. Frailty measures such as the Charlson Comorbidity Index were unavailable.
Why this study matters
In this individual patient-level meta-analysis of six randomized trials, daratumumab-containing regimens were associated with higher rates of any-grade, severe, respiratory, and recurrent infections than non-daratumumab-containing regimens in patients with MM. Infection risk was highest during the first three months of treatment, and adjusted analyses showed associations between daratumumab use and increased early infection risk. Secondary IVIG prophylaxis after a first documented grade ≥3 respiratory infection was received by 18.5% of daratumumab-treated patients who experienced such an infection; interpretation of the findings is subject to limitations including incomplete pathogen information, inconsistent documentation of antimicrobial prophylaxis duration, and the use of clinical trial populations that may not represent patients treated in routine clinical practice.
Reference:
Visram A, Mian H, Lee J, Jones A, Pond GR, Hansen D, et al. Temporal trends in infectious risk among multiple myeloma patients treated with daratumumab: A meta-analysis. Br J Haematol. 2026; 00: 1–11. https://doi.org/10.1111/bjh.70882
Beyond binary: graded frailty assessment and outcomes after CAR-T cell therapy in relapsed/refractory multiple myeloma — Blood Cancer Journal (October 2026)
What is the purpose of the study?
To compare the Simplified Frailty Index (SFI) and the Memorial Sloan Kettering Frailty Index (MSK-FI) for assessing frailty and evaluating their associations with efficacy and safety outcomes in patients with relapsed/refractory multiple myeloma (RRMM) receiving chimeric antigen receptor (CAR)-T cell therapy. The study also examines whether frailty scores analyzed as continuous measures or binary categories were associated with clinical outcomes.
Summary
This retrospective cohort study included 118 patients with RRMM who received CAR-T cell therapy at Memorial Sloan Kettering Cancer Center between March 2018 and March 2025. The SFI classified 15% of patients as frail, while the MSK-FI classified 25% as frail, with 75% agreement between the instruments. After adjustment for extramedullary disease and bone marrow disease burden, continuous MSK-FI scores were associated with progression-free survival (PFS; hazard ratio [HR] 1.21, 95% confidence interval [CI] 1.03–1.43; p = 0.027), whereas continuous SFI scores were not significantly associated with PFS or overall survival (OS). Neither instrument's binary frailty classification was significantly associated with PFS, OS, or the assessed safety outcomes.
Key points
Study design and methods
• Study type: Retrospective cohort study
• Population: 118 patients with RRMM who received CAR-T cell therapy between March 2018 and March 2025
• CAR-T products: Ciltacabtagene autoleucel (cilta-cel), 68 patients (58%); idecabtagene vicleucel (ide-cel), 32 patients (27%); and investigational anti-B-cell maturation antigen (BCMA) CAR-T, 18 patients (15%)
• Frailty assessments:
- Simplified Frailty Index (SFI): Incorporates age, Eastern Cooperative Oncology Group (ECOG) performance status, and Charlson Comorbidity Index; scores range from 0 to 5, with SFI ≥2 defining frailty.
- Memorial Sloan Kettering Frailty Index (MSK-FI): Incorporates limitations in selected activities of daily living (ADL) or instrumental activities of daily living (IADL) and 10 comorbidity domains; scores range from 0 to 11, with MSK-FI ≥3 used to define frailty.
• Primary outcomes: PFS, OS, all-grade infection within 90 days of infusion, and 1-year all-cause mortality.
• Statistical methods: Cox proportional hazards regression and logistic regression, with multivariable models adjusted for extramedullary disease (EMD) and bone marrow disease burden.
Main findings
• Frailty classification: The SFI classified 18 patients (15%) as frail, compared with 30 (25%) using the MSK-FI. Overall agreement was 75% (88/118), indicating that the instruments classified partially overlapping but distinct patient groups.
• Progression-free survival: Continuous MSK-FI scores were significantly associated with PFS after adjustment for EMD and bone marrow disease burden (HR 1.21, 95% CI 1.03–1.43; p = 0.027). Continuous SFI scores were not significantly associated with PFS (HR 1.30, 95% CI 0.91–1.85; p = 0.2).
• Overall survival: Neither continuous MSK-FI scores (HR 1.20, 95% CI 0.98–1.46; p = 0.080) nor continuous SFI scores (HR 1.54, 95% CI 0.99–2.39; p = 0.054) were significantly associated with OS.
• One-year mortality: Continuous SFI scores were associated with 1-year all-cause mortality in univariable analysis (odds ratio [OR] 2.51, 95% CI 1.20–5.57; p = 0.014). This association was not statistically significant when SFI was dichotomized using the established frailty threshold (OR 1.86, 95% CI 0.54–5.67; p = 0.3).
• Safety outcomes: Neither frailty instrument was significantly associated with 90-day infection, any-grade cytokine release syndrome (CRS), or grade ≥3 cytopenia in the reported post-hoc analyses.
• Disease progression and follow-up: Among patients without progression at the relevant assessment, median follow-up was 22 months (interquartile range 15–28). During the study, 76 patients experienced disease progression and 49 died. Median PFS was 12 months (95% CI 9.8–19 months).
• Binary frailty analyses: Neither instrument's binary frailty classification showed a statistically significant association with PFS or OS in the reported multivariable analyses.
Strengths
• Direct comparison of two structurally distinct frailty instruments in the same RRMM CAR-T cohort.
• Use of a validated, myeloma-specific instrument (SFI) alongside an exploratory application of the MSK-FI, which had not previously been validated in multiple myeloma.
• Adjustment for EMD and bone marrow disease burden, identified a priori as determinants of CAR-T outcomes.
• Evaluation of frailty scores as both continuous measures and binary categories.
Limitations
• The small sample size and low event rates limited statistical power to evaluate alternative MSK-FI cutoffs and formally compare the instruments' discrimination and calibration.
• The MSK-FI has not been previously validated in a myeloma-specific or CAR-T population; its use in this study was exploratory.
• Multivariable models adjusted only for EMD and bone marrow disease burden, without additional adjustment for age, high-risk cytogenetics, CAR-T product, or treatment era.
• Selection bias associated with CAR-T referral and treatment may have limited representation of the full spectrum of frailty among eligible patients.
• All 18 patients classified as frail by SFI had high disease burden, complicating the distinction between frailty and disease severity in this subgroup.
• Neither instrument assesses cognition, nutrition, social support, psychological health, or objective physical performance, as included in comprehensive geriatric assessment.
• The study did not formally compare the instruments' discrimination, calibration, or incremental prognostic value.
• The findings do not establish that either frailty index should guide CAR-T eligibility or patient counseling.
Why this study matters
In this retrospective cohort of 118 patients with RRMM receiving CAR-T cell therapy, the SFI and MSK-FI showed 75% classification concordance, and only continuous MSK-FI scores were significantly associated with PFS in multivariable analysis. Binary frailty classifications were not significantly associated with efficacy or safety outcomes, while continuous SFI scores were associated with 1-year all-cause mortality only in univariable analysis. Prospective validation in larger cohorts is required to determine whether these findings generalize to other populations and whether either instrument provides clinically useful prognostic information.
Reference:
Hashmi, H., Han, K., McCready, T. et al. Beyond binary: graded frailty assessment and outcomes after CAR-T cell therapy in relapsed/refractory multiple myeloma. Blood Cancer J. 16, 192 (2026). https://doi.org/10.1038/s41408-026-01653-1
FedMann: A Manually Coordinated Federated Learning Framework Applied to Multiple Myeloma—A Feasibility Study — Journal of Clinical Medicine (October 2026)
What is the purpose of the study?
To develop and assess the feasibility of FedMann, a manually coordinated federated learning (FL) framework that enables multiple clinical institutions to train predictive models without exchanging patient-level data or requiring dedicated FL infrastructure. The framework was applied to predict non-receipt of guideline-concordant primary therapy among patients with newly diagnosed multiple myeloma (MM) at two clinical sites with substantially different patient populations.
Summary
This retrospective cohort study analyzed electronic health record data from 5,148 patients with newly diagnosed MM at the Veterans Affairs (VA) Healthcare System (n = 4,887) and Boston Medical Center (BMC; n = 261) between 2012 and 2022. FedMann used sample-size-weighted parameter averaging to combine locally trained models, which were evaluated on site-specific held-out test sets using the area under the receiver operating characteristic curve (AUC). The federated model achieved an AUC of 0.68 (95% CI, 0.55–0.80) on the BMC test set and 0.70 (95% CI, 0.67–0.72) on the VA test set, with no statistically significant differences between models on the BMC test set; the findings demonstrated the framework’s feasibility, although absolute model discrimination was modest.
Key points
• Study design and population: Retrospective cohort study of patients newly diagnosed with MM at two clinical sites between 2012 and 2022: VA (4,887 patients) and BMC (261 patients).
• Prediction objective: To predict non-receipt of guideline-concordant primary therapy, defined as not receiving a frontline triplet or quadruplet regimen or autologous stem cell transplant when eligible.
• Framework and methodology: FedMann used a four-stage process consisting of local model training, parameter sharing through an access-controlled repository, sample-size-weighted parameter averaging at a coordinating site, and redistribution of the federated model. Patient-level data were not exchanged.
• Differences between sites: The patient populations differed substantially across all measured demographic characteristics. The proportion of male patients was 96.3% at VA and 58.6% at BMC (p < 0.001).
• Model performance:
- The BMC-only model achieved an AUC of 0.70 (95% CI, 0.56–0.81) on the BMC test set.
- The federated model achieved an AUC of 0.68 (95% CI, 0.55–0.80) on the BMC test set and 0.70 (95% CI, 0.67–0.72) on the VA test set.
- The VA-only model achieved an AUC of 0.68 on the BMC test set.
- No pairwise differences between models on the BMC test set were statistically significant.
• Implementation requirements: After cloning the FedMann repository, each federated round required five Python commands. Two site representatives completed all three rounds in approximately 30 minutes. Standardized, preprocessed training, and test data were required at each site.
Strengths
• Demonstrated multi-institutional model fitting without exchanging patient-level data.
• Operated without dedicated FL infrastructure, including the servers and firewall modifications generally required by automated FL systems.
• Evaluated model performance across two sites with substantially different patient populations.
• Included an equal-weighting sensitivity analysis to examine the effect of aggregation weights.
Limitations
• Absolute AUC values were modest, and confidence intervals for site-specific estimates were wide.
• The BMC test set was small, and the sample sizes of the two sites were substantially imbalanced.
• A single train/test split was used instead of repeated stratified resampling.
• Data heterogeneity limited the number of predictors that could be harmonized across sites.
• A centralized benchmark trained on pooled patient-level data was not feasible because data-use agreements prohibited pooling records across sites.
• Parameter sharing alone does not provide formal cryptographic privacy guarantees against model inversion or membership inference attacks.
• The study was a feasibility evaluation, not a scalability study, and the predictive model was not ready for clinical deployment.
Why this study matters
FedMann demonstrated the feasibility of manually coordinated federated learning for fitting predictive models across two clinical sites without exchanging patient-level data or requiring dedicated FL infrastructure. The federated model achieved AUCs of 0.68 on the BMC test set and 0.70 on the VA test set, with no statistically significant pairwise differences between models on the BMC test set. Further evaluation across additional clinical sites and model classes, improvements in formal privacy protections, and additional model development and prospective evaluation are needed before broader deployment or clinical use.
Reference:
Sommers, S. W., Zheng, C., Corrigan, J. K., Culnan, J. M., Bodanapu, G., Ferri, G. M., Abdallah, M., Bell, B., Yellanki, M., Elbers, D. C., Do, N. V., Brophy, M. T., Munshi, N. C., Edwards, C. V., & Fillmore, N. R. (2026). FedMann: A Manually Coordinated Federated Learning Framework Applied to Multiple Myeloma—A Feasibility Study. Journal of Clinical Medicine, 15(21), 8418. https://doi.org/10.3390/jcm15218418
Teclistamab Plus Daratumumab Versus Standard Daratumumab-Based Proteasome Inhibitor Combinations for Relapsed/Refractory Multiple Myeloma: An Inverse Probability of Treatment Weighting Analysis — Advances in Therapy (November 2026)
What is the purpose of the study?
To compare the efficacy of teclistamab plus daratumumab (Tec-Dara) with two proteasome inhibitor (PI)-based regimens, daratumumab/carfilzomib/dexamethasone (DKd) and daratumumab/bortezomib/dexamethasone (DVd), in patients with relapsed/refractory multiple myeloma (RRMM) who had received 1–3 prior lines of therapy (pLOTs). Using individual patient-level data (IPD) and inverse probability of treatment weighting (IPTW), the study seeks to further evaluate the comparative effects of these regimens on survival and treatment response.
Summary
This adjusted indirect treatment comparison used IPD from three phase 3 clinical trials: MajesTEC-3 (NCT05083169), CANDOR (NCT03158688), and CASTOR (NCT02136134). After IPTW adjustment for differences in baseline patient characteristics, Tec-Dara was associated with significantly longer progression-free survival (PFS) and overall survival (OS) than DKd and DVd, as well as higher rates of overall response rate (ORR), very good partial response or better (≥VGPR), and complete response or better (≥CR). The findings were consistent across sensitivity analyses, although the comparison was indirect rather than based on a head-to-head randomized clinical trial.
Key points
Study design and population
• Adjusted indirect treatment comparison using IPD from MajesTEC-3, CANDOR, and CASTOR.
• Included patients with RRMM who had received 1–3 pLOTs.
• Compared Tec-Dara with two PI-based regimens: DKd and DVd.
• IPTW was used to adjust for differences in baseline patient characteristics.
Progression-free survival (PFS)
• Tec-Dara was associated with significantly improved PFS compared with:
- DKd: HR 0.22 (95% CI 0.15–0.33; P < 0.001).
- DVd: HR 0.11 (95% CI 0.07–0.17; P < 0.001).
Overall survival (OS)
• Tec-Dara was associated with significantly improved OS compared with:
- DKd: HR 0.40 (95% CI 0.26–0.61; P < 0.001).
- DVd: HR 0.24 (95% CI 0.14–0.40; P < 0.001).
Treatment response
• Tec-Dara was associated with higher response rates than DKd and DVd
• Relative likelihood of achieving:
- Overall response rate (ORR): RR 1.11 versus DKd and 1.10 versus DVd.
- Very good partial response or better (≥VGPR): RR 1.33 versus DKd and 2.20 versus DVd.
- Complete response or better (≥CR): RR 2.84 versus DKd and 5.17 versus DVd.
Robustness of findings
• Sensitivity analyses included alternative weighting approaches (ATE, ATC, and ATO), multivariable regression, and doubly robust methods.
• Results consistently favored Tec-Dara across PFS, OS, and response outcomes.
Treatment characteristics
• Tec-Dara was described as a steroid-sparing regimen.
• The regimen includes a monthly dosing schedule from cycle 7.
Strengths
• Used individual patient-level data from three pivotal clinical trials rather than relying solely on aggregated data.
• Applied IPTW to adjust for differences in baseline characteristics and improve comparability between treatment cohorts.
• Conducted multiple sensitivity analyses using alternative weighting and statistical methods.
• Included several clinically relevant efficacy outcomes, including PFS, OS, ORR, ≥VGPR, and ≥CR.
Limitations
• The analysis was an indirect cross-trial comparison rather than a head-to-head randomized clinical trial; therefore, residual confounding may remain.
• Cytogenetic risk was not adjusted for in the DKd analysis because of substantial missing data.
• The proportion of patients with extramedullary disease (EMD) was limited in both cohorts, potentially affecting generalizability.
• Low levels of prior anti-CD38 exposure and differences in trial eligibility criteria prevented meaningful conclusions regarding the effects of previous anti-CD38 treatment.
• Differences in median follow-up between trials may have affected OS comparisons.
• Differences in the availability of subsequent therapies between the CANDOR/CASTOR and MajesTEC-3 treatment eras may have influenced OS outcomes.
• A formal lenalidomide-refractory subgroup analysis was not conducted because of its potential impact on effective sample size.
Why this study matters
In this IPTW-adjusted indirect comparison, Tec-Dara was associated with significantly improved PFS and OS and higher rates of ORR, ≥VGPR, and ≥CR compared with DKd and DVd in patients with RRMM who had received 1–3 pLOTs. The findings were consistent across sensitivity analyses but remain subject to the limitations of cross-trial comparisons, including potential residual confounding, differences in follow-up, and variations in subsequent treatment availability. The results further support the use of Tec-Dara as a standard-of-care treatment option for RRMM as early as first relapse.
Reference:
Anderson, L.D., Nair, S., Keng, M.J. et al. Teclistamab Plus Daratumumab Versus Standard Daratumumab-Based Proteasome Inhibitor Combinations for Relapsed/Refractory Multiple Myeloma: An Inverse Probability of Treatment Weighting Analysis. Adv Ther (2026). https://doi.org/10.1007/s12325-026-03832-9
Spatial Profiling Identifies a Distinct and Topographically Defined Tumor Microenvironment that Emerges during Multiple Myeloma Evolution — Blood Cancer Discovery (November 2026)
What is the purpose of the study?
To characterize the spatial organization and cellular composition of the bone marrow (BM) tumor microenvironment (TME) in multiple myeloma across different stages of disease evolution. It also investigates the relationship between tumor growth architecture, BM cellular populations, and clinical outcomes, including overall survival (OS) and progression-free survival (PFS).
Summary
Using spatial transcriptomics (ST) and imaging mass cytometry (IMC), researchers investigated the spatial distribution of multiple myeloma cells and their surrounding BM cellular environment. They found that myeloma cells, initially distributed as scattered cells or small clusters, formed dense tumor nodules during disease evolution, characterized by enrichment of macrophages, conventional dendritic cells (cDCs), CD8+ T cells, endothelial cells (ECs), and THY1+ mesenchymal stromal cells (MSCs), while neutrophil-lineage cells were largely absent. In a separate clinical outcome analysis involving 153 patients enrolled in the HOVON87/NMSG18 trial, dense nodular and sheet-like tumor architectures were associated with inferior clinical outcomes independently of BM plasma cell (BMPC) infiltration.
Key points
Main findings
• Spatial organization of multiple myeloma: Myeloma cells initially appeared as scattered cells or small clusters throughout the BM. With disease evolution, they increasingly condensed into dense tumor nodules characterized by a distinct cellular microenvironment.
• Cellular composition of dense tumor nodules: Dense regions were enriched in:
- Macrophages
- Conventional dendritic cells (cDCs)
- CD8+ T cells, including activated/exhausted T-cell populations
- Endothelial cells (ECs) and sinusoidal endothelial cells (SECs)
- THY1+ mesenchymal stromal cells (MSCs)
• Neutrophil distribution: Neutrophil-lineage cells were largely absent from dense tumor nodules but interacted with scattered myeloma cells outside these regions. At any given moment, at least 50% of plasma cells in scattered regions were interacting with a neutrophil-lineage cell.
• Macrophage enrichment: Macrophages remained present in dense tumor nodules and represented the most prevalent immune population in absolute cell numbers. The authors discuss macrophages as potential alternative sources of BCMA- and TACI-related survival signals and as cells associated with angiogenesis and immunosuppression. remained present in dense tumor nodules and represented the most prevalent immune population in absolute cell numbers. The authors discuss macrophages as potential alternative sources of BCMA- and TACI-related survival signals and as cells associated with angiogenesis and immunosuppression.
• T-cell findings: Dense tumor regions showed enrichment of conventional dendritic cells and CD8+ T cells, including activated/exhausted T-cell patterns. However, the study could not definitively distinguish recently activated T cells from exhausted T cells using the available imaging mass cytometry panel.
• Stromal and vascular changes: THY1+ MSCs, ECs, and SECs were increased in dense tumor regions, indicating differences in the cellular composition of the stromal and vascular compartments.
• Clinical outcomes: In the HOVON87/NMSG18 trial cohort, BM biopsies from 153 patients were evaluated for plasma cell growth architecture. Dense nodular and sheet-like patterns were associated with inferior clinical outcomes, independently of BMPC infiltration. Clinical outcomes evaluated included OS and PFS, alongside R-ISS stage and cytogenetic information.
• Disease-stage distribution: Dense myeloma TMEs were detected only at symptomatic disease stages in the analyzed cohorts. However, the relatively low BM infiltration in the analyzed SMM samples and the limited cohort size prevented the researchers from excluding the presence of dense nodules in precursor disease.
• Tumor architecture at relapse: A small number of relapsed/refractory multiple myeloma (RRMM) samples showed two distinct patterns: scattered plasma cells and dense tumor nodules. The study could not establish whether these patterns reflected the tumor architecture before treatment.
• 5TGM1 mouse model: The 5TGM1 transfer model reproduced aspects of human BM tumor architecture, including dense nodules, neutrophil exclusion, and preservation of macrophages.
Methodological features
The following methodological features were reported in the study:
• Complementary spatial technologies: The use of ST and IMC enabled characterization of BM cellular composition and spatial organization at the tissue and cellular levels.
• Multiple disease stages: The investigation included high-risk smoldering multiple myeloma (SMM), newly diagnosed multiple myeloma (NDMM), primary plasma cell leukemia (pPCL), and RRMM.
• Clinical outcome evaluation: Tumor growth patterns were assessed in 153 patients enrolled in the HOVON87/NMSG18 trial, with clinical outcome information available for 137 patients.
• Independent tumor architecture assessment: Two investigators independently scored BM samples while blinded to BMPC percentages and each other's assessments. Discrepancies were resolved by a third reviewer.
• Multivariable statistical analysis: Multivariable Cox proportional hazards regression models were used to evaluate the prognostic association of tumor architecture, including models with and without BMPC infiltration as a covariate.
• Additional experimental evaluation: Selected findings were examined using an independent IMC cohort and the 5TGM1 mouse model.
Limitations
The authors explicitly acknowledged the following limitations:
• Limited sample sizes: Sample sizes were determined by the availability of high-quality tissue without prior power analysis. The final ST cohort consisted of 20 samples: SMM (n = 4), NDMM (n = 5), pPCL (n = 3), RRMM (n = 3), and control BM (n = 5).
• Insufficient statistical power: The cohorts were not sufficiently powered to exclude dense tumor nodules in precursor disease or detect differences between genomic subgroups and tumor topographies.
• Limited T-cell characterization: The IMC panel could not adequately distinguish closely related T-cell subsets, preventing definitive differentiation between recently activated and exhausted CD8+ T cells.
• Uncertain findings in precursor disease: The relatively low BM infiltration in the analyzed SMM samples prevented the researchers from excluding an association between tumor burden and dense nodule formation. Larger cohorts encompassing a broader range of infiltration levels are required.
• Limited relapse assessment: The small and heterogeneous relapse cohort did not allow the researchers to determine whether tumor architecture at relapse reflected the architecture before treatment. Longitudinal sampling is needed to investigate this question.
• Unresolved biological differences: Whether myeloma cells in dense nodules differ biologically or in their mutational signatures from scattered myeloma cells remains unknown.
• Limited differential expression sample size: Although a region-based pseudobulk approach was used to account for patient variation and spatial heterogeneity, the overall sample size remained limited. Therefore, the authors advised cautious interpretation of P values, emphasizing effect sizes and consistency across regions.
• Uncertain relationship with focal lesions: Whether dense BM nodules represent early architectural precursors of radiologically detectable focal lesions (FLs) remains unclear.
Why this study matters
The study identified a spatially defined multiple myeloma TME characterized by dense tumor nodules enriched in macrophages, conventional dendritic cells, CD8+ T cells, endothelial cells, and THY1+ mesenchymal stromal cells, with relative exclusion of neutrophil-lineage cells. In the HOVON87/NMSG18 trial cohort, dense nodular and sheet-like tumor architectures were associated with inferior clinical outcomes independently of BMPC infiltration. Larger patient cohorts and longitudinal studies are needed to clarify the development, biological characteristics, and clinical significance of these spatial tumor patterns.
Reference:
Marnix Koops, Luca Bertamini, Natalie Papazian, Charlotte Korst, Mátyás János Budai, Remco M. Hoogenboezem, Mathijs A. Sanders, Bronno van der Holt, Mark van Duin, Annemiek Broijl, Péter Balogh, Sonja Zweegman, Marc H.G.P. Raaijmakers, Niels W.C.J. van de Donk, Zoltán Kellermayer, Pieter Sonneveld, Tom Cupedo; Spatial Profiling Identifies a Distinct and Topographically Defined Tumor Microenvironment that Emerges during Multiple Myeloma Evolution. Blood Cancer Discov 1 November 2026; 7 (6): 999–1016. https://doi.org/10.1158/2643-3230.BCD-26-0080
Genomics-Guided Risk Stratification in Myeloma Precursor Conditions: Converging Frameworks From Whole-Genome Sequencing — Technology in Cancer Research & Treatment (November 2026)
What is the purpose of the study?
To critically review three landmark 2025 cohort studies using whole-exome sequencing (WES) and whole-genome sequencing (WGS) to identify genomic features associated with the development and progression of multiple myeloma (MM) from its precursor conditions, monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). It aims to synthesize the convergent findings of these studies into a practical approach for genomics-guided risk assessment and management of myeloma precursor conditions.
Summary
This perspective reviewed three genomic frameworks proposed in 2025 by Maura et al., Aktas Samur et al., and Alberge et al. to characterize malignant genomic transformation and progression risk in MGUS and SMM. The studies found that genomic alterations associated with overt MM are frequently established before clinical progression: approximately 60% of clinically defined MGUS and 10% of SMM were classified as genomic MGUS by Maura et al., while more than 80% of driver events in paired SMM and MM samples were already detectable at the SMM stage. Collectively, the findings indicate that WES/WGS-derived genomic features meaningfully improve clinical risk models by identifying genomic characteristics that may not be captured by conventional clinical criteria.
Major findings
Genomic classification of MGUS and SMM (Maura et al.)
• Identified 28 myeloma-defining genomic events, including initiating translocations, hyperdiploidy, RAS pathway mutations, APOBEC (apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like) mutagenesis, and specific copy-number alterations.
• Approximately 60% of clinically defined MGUS and 10% of clinically defined SMM lacked evidence of genomic malignant transformation and were classified as genomic MGUS.
• No patients classified as genomic MGUS progressed to symptomatic MM during a median follow-up of 46 months in either the training or validation cohorts.
• The remaining patients already exhibited a full complement of genomic aberrations characteristic of overt MM despite being asymptomatic.
Longitudinal genomic evolution (Aktas Samur et al.)
• In 51 patients with matched SMM and MM specimens, more than 80% of driver events were already detectable at the SMM stage.
• Sixty-six percent demonstrated static clonal evolution, with no change in clonal composition at the time of progression.
• These findings support the presence of established malignant genomic architecture before clinical progression.
MM-like genomic score (Alberge et al.)
• Developed an MM-like score based on 24 recurrent MM drivers, including mutations, translocations, and copy-number changes.
• Each MM-associated driver contributed one point, while each MGUS-associated driver subtracted one point.
• Median MM-like scores increased across disease stages: one in MGUS, two in SMM, and three in MM.
• Among 20 patients with serial samples, those who subsequently progressed had a higher baseline median score than non-progressors (three versus one).
• New driver events continued to accumulate during follow-up, indicating that genomic evolution continued even after the baseline assessment.
Convergent implications of the three frameworks
• The malignant genomic architecture of MM is frequently established before clinical progression.
• Some patients clinically classified as MGUS or SMM already exhibit genomic characteristics associated with overt MM.
• WES/WGS-derived genomic features meaningfully improve clinical risk models and may help distinguish genomic disease states not adequately captured by conventional clinical classifications.
• The three frameworks use different approaches: Maura et al. employ a binary classification based on defining genomic events; Aktas Samur et al. examine longitudinal clonal evolution; and Alberge et al. use a graded MM-like genomic score.
Limitations and caveats
• Cohort selection bias: Maura et al.'s cohort was enriched for bone-marrow-biopsied MGUS patients, potentially overestimating the prevalence of genomically malignant MGUS because it under-represented the broader population of low-risk MGUS patients who do not undergo biopsy.
• Sequencing detection limits: Subclonal genomic events below the detection threshold of bulk sequencing may harbor transformation-associated alterations.
• Insufficient follow-up duration: The median follow-up of 46 months may be insufficient to establish genomic MGUS as a biologically distinct, non-progressing entity, given that MM may take 30–40 years to develop from initiation to clinical disease.
• Small external validation subgroup: Alberge et al. identified only three patients with an MM-like score of −1 in an external cohort. None progressed, but two remained under observation at five years. The subgroup was too small to independently support the genomic MGUS designation.
• Differences in genomic classification approaches:
- Maura et al. use a non-compensatory approach in which the presence of any single defining genomic event is sufficient to classify a patient as genomic MM.
- Alberge et al. use a compensatory scoring approach in which MGUS-associated drivers subtract from the MM-like score.
- Consequently, the frameworks measure different aspects of genomic disease status: the presence of defining malignant alterations versus the degree of genomic resemblance to overt MM.
Why this study matters
The three 2025 genomic frameworks indicate that many genomic alterations characteristic of overt MM are already present during the MGUS and SMM stages, before clinical progression. WES/WGS-derived genomic features meaningfully improve clinical risk models through the identification of malignant genomic characteristics and the assessment of progression risk. However, the interpretation of genomic MGUS remains subject to limitations, particularly cohort selection bias, sequencing detection thresholds, insufficient follow-up duration, and small subgroup sizes; therefore, longer-term validation is needed to establish its biological and clinical significance.
Reference:
Xiong X, Wang X, Li J, Shen K. Genomics-Guided Risk Stratification in Myeloma Precursor Conditions: Converging Frameworks From Whole-Genome Sequencing. Technology in Cancer Research & Treatment. 2026;25. doi:10.1177/15330338261503783
Increased Overall Survival for Subcutaneous Versus Intravenous Daratumumab in Medicare Beneficiaries With Multiple Myeloma — Clinical Lymphoma Myeloma and Leukemia (November 2026)
What is the purpose of the study?
To compare real-world overall survival (rwOS) among Medicare beneficiaries aged 65 years or older with multiple myeloma (MM) who received subcutaneous daratumumab co-formulated with recombinant human hyaluronidase PH20 (Dara PH20 SC) versus intravenous daratumumab (Dara IV). The study also evaluates differences in serious infections, treatment discontinuation, and other exploratory effectiveness and safety outcomes.
Summary
This retrospective observational study analyzed Medicare claims data to compare rwOS between patients with MM receiving Dara PH20 SC or Dara IV. Among 14,618 eligible patients, propensity-score matching identified 1,191 patients per treatment group; Dara PH20 SC was associated with a lower risk of all-cause mortality than Dara IV (HR: 0.76; 95% CI: 0.67–0.86; P < .001), as well as lower risks of serious infections (HR: 0.87; 95% CI: 0.78–0.97; P < .01) and treatment discontinuation (HR: 0.72; 95% CI: 0.66–0.79; P < .01). No significant differences were observed in exploratory effectiveness outcomes, including time to next treatment, time to relapse or next treatment, and time to new CRAB events (hypercalcemia, renal failure, anemia, and bone lesions).
Key points
Study design and population
• Retrospective comparative effectiveness and safety study using US Medicare fee-for-service, Medicare Advantage, and Part D claims data.
• Included Medicare beneficiaries aged 65 years or older with MM who received either Dara PH20 SC or Dara IV.
• A total of 14,618 eligible patients were identified:
- Dara PH20 SC: 8,324 patients.
- Dara IV: 6,294 patients.
• After propensity-score matching, 1,191 patients were included in each treatment group.
• The primary endpoint was rwOS, defined as the time from treatment initiation to death from any cause.
• Exploratory endpoints included serious infections, serious events, time to next treatment, time to relapse or next treatment, new CRAB events, and daratumumab treatment discontinuation.
Main findings
• Overall survival: Dara PH20 SC was associated with a lower risk of all-cause mortality compared with Dara IV (HR: 0.76; 95% CI: 0.67–0.86; P < .001).
• Serious infections: Dara PH20 SC was associated with a lower risk of serious infections requiring hospitalization or intravenous antibiotics (HR: 0.87; 95% CI: 0.78–0.97; P < .01).
• Treatment discontinuation: Dara PH20 SC was associated with a lower risk of treatment discontinuation (HR: 0.72; 95% CI: 0.66–0.79; P < .01).
• Treatment duration: Patients receiving Dara PH20 SC had a longer treatment duration than those receiving Dara IV.
• Exploratory effectiveness outcomes: No significant differences were observed in real-world time to next treatment (rwTTNT), time to relapse or next treatment (rwTTRNT), or time to new CRAB events (rwTTCRAB).
• First-line treatment subgroup: The association between Dara PH20 SC and improved rwOS was also observed among patients receiving daratumumab as first-line treatment.
Strengths
• Large, nationally representative Medicare population.
• Use of rwOS, an objective clinical endpoint.
• Rigorous confounding control using exact matching, propensity-score matching, and residual covariate adjustment.
• Sensitivity analyses were conducted to assess the robustness of the findings.
• Study protocol and analysis plans were finalized before analysis of the prespecified primary endpoint.
Limitations
• Reliance on administrative claims data, which may undercount treatments bundled for reimbursement, including dexamethasone used as daratumumab pretreatment.
• Lack of detailed clinical information, including cytogenetic characteristics and differentiation between newly diagnosed MM (NDMM) and relapsed or refractory MM (RRMM).
• Absence of laboratory values and imaging results, requiring the use of CRAB criteria rather than laboratory data needed for Revised International Staging System classification.
• Potential residual confounding despite extensive adjustment.
• Immunoglobulin replacement therapy (IgRT) use was not included as a prespecified confounder, although post hoc analyses found no significant differences in its use between treatment groups.
Why this study matters
Among Medicare beneficiaries with MM, Dara PH20 SC was associated with improved rwOS compared with Dara IV, with a 24% lower relative hazard of all-cause mortality. This association occurred alongside lower risks of serious infections and treatment discontinuation and longer treatment duration, while exploratory effectiveness outcomes related to relapse, subsequent treatment, and CRAB events did not differ significantly. Because the study was observational and based on administrative claims, the findings should be considered in the context of potential residual confounding and limitations in clinical data availability.
Reference:
Daniel Gomes, Phillip Sarocco, Charles P. Theuer, Gareth Morgan, Todd Kennedy, Paul Santos Estrella, Jimmy Zhou, Saad Z. Usmani, Increased Overall Survival for Subcutaneous Versus Intravenous Daratumumab in Medicare Beneficiaries With Multiple Myeloma, Clinical Lymphoma Myeloma and Leukemia, 2026, ISSN 2152-2650, https://doi.org/10.1016/j.clml.2026.08.016.
Bone recovery after treatment study: Evidence of myeloma bone disease repair and partial microenvironment recovery — British Journal of Haematology (November 2026)
What is the purpose of the study?
To assess the feasibility of monitoring changes in bone health, osteolytic lesions, and the bone microenvironment in patients with newly diagnosed multiple myeloma undergoing first-line treatment. It also aims to generate preliminary data to guide the design of a larger study and inform future clinical trials of bone-targeted therapies.
Summary
This prospective, observational, single-center pilot study evaluated bone recovery in patients with newly diagnosed multiple myeloma receiving first-line therapy, including Velcade-thalidomide-dexamethasone (VTd), zoledronic acid, and, where applicable, autologous stem cell transplantation (ASCT). Bone changes were assessed using whole-body low-dose computed tomography (WBLDCT), bone marrow trephine biopsies, and monthly bone turnover markers (CTX-I, P1NP, and sclerostin) at baseline and during follow-up. All nine patients demonstrated partial repair of some osteolytic lesions, accompanied by increased trabecular bone volume and osteoblast numbers; however, osteocyte lacunar canalicular network (LCN) coverage decreased, and complete lesion resolution was uncommon.
Key points
Study design and assessment
• Prospective, observational, single-centre pilot study.
• Evaluated patients with newly diagnosed multiple myeloma undergoing first-line treatment.
• Bone health assessments included:
• WBLDCT to evaluate osteolytic lesions.
• Bone marrow trephine biopsies to assess trabecular bone microarchitecture, osteoblasts, osteoclasts, and the osteocyte LCN.
• Monthly measurements of bone turnover markers: CTX-I, P1NP, and sclerostin.
• Assessments were conducted at baseline and during follow-up after induction therapy and/or ASCT.
Main findings
• Osteolytic lesion repair: All nine patients (100%) demonstrated a reduction in the size of some or all osteolytic lesions. However, repair varied between skeletal sites, and complete resolution was uncommon. One patient experienced complete resolution of 24% of baseline osteolytic lesions.
• Trabecular bone volume: Increased significantly following treatment.
• p=0.003p=0.003.
•Osteoblast numbers: Increased significantly at follow-up.
• p<0.05p<0.05
• Osteocyte lacunar canalicular network: Canalicular coverage decreased significantly.
• p<0.01p<0.01
• Bone turnover markers:
- Serum CTX-I was significantly suppressed from month 2 (p<0.0001p<0.0001).
- Sclerostin levels decreased significantly from month 3 (p=0.011p=0.011).
- The findings demonstrated changes in bone structure and bone turnover during first-line myeloma treatment.
Strengths
• The study demonstrated the feasibility and acceptability of comprehensive longitudinal bone health assessments during first-line myeloma treatment.
• Patients were consulted during study conceptualization to assess the relevance and acceptability of the research.
• Multiple assessment methods were used, including imaging, bone histology, microarchitecture analysis, and biochemical bone turnover markers.
• The pilot provided preliminary data to inform modifications to the subsequent BRATS recruitment cohort and the selection of endpoints for future studies.
Limitations
• The pilot involved a small cohort of nine patients, limiting the ability to draw firm conclusions.
• Formal power calculations were not performed because the study was exploratory.
• The study was conducted at a single centre.
• Subsequent treatment regimens varied among participants, although all initially received VTD and zoledronic acid.
• Follow-up duration was limited, and a longer follow-up period was identified as necessary.
• Patient-reported outcome measures (PROMs) were incomplete and did not adequately assess bone pain and quality of life.
• The impact of myeloma and treatment on the osteocyte LCN remains insufficiently understood, limiting interpretation of the observed changes.
Why this study matters
This pilot study demonstrated the feasibility of longitudinally assessing bone health in patients with newly diagnosed multiple myeloma receiving first-line treatment. Although all nine patients showed partial repair of osteolytic lesions, with significant increases in trabecular bone volume and osteoblast numbers, osteocyte LCN coverage decreased, and complete lesion resolution remained uncommon. These preliminary findings support further investigation of bone recovery mechanisms and the development of future studies evaluating bone-targeted therapies for myeloma bone disease (MBD).
Reference:
Andrews RE, Jolley I, Evans H, Lath D, Sharma V, Brown JE, et al. Bone recovery after treatment study: Evidence of myeloma bone disease repair and partial microenvironment recovery. Br J Haematol. 2026; 00: 1–11. https://doi.org/10.1111/bjh.70903
MRD dynamics predicts progression and reveals a vulnerable state for immunotherapy interception in multiple myeloma — Blood (November 2026)
What is the purpose of the study?
To investigate the prognostic significance of serial measurable residual disease (MRD) assessments in patients with multiple myeloma (MM), identify patient subgroups according to MRD dynamics, and characterize the molecular and immune mechanisms associated with MRD resistance. The study also evaluated whether treating persistent MRD with anti–B-cell maturation antigen (anti-BCMA) chimeric antigen receptor (CAR) T cells, rather than waiting until clinical relapse, could prolong survival in human-like MM mouse models.
Summary
This study evaluated longitudinal MRD dynamics in 539 patients with newly diagnosed MM enrolled in the GEM2012MENOS65/GEM2014MAIN and GEM2017FIT clinical trials, using 3,610 MRD assessments, with independent validation in 249 patients treated in routine clinical practice. Five MRD subgroups with distinct survival outcomes were identified, and MRD dynamics demonstrated stronger prognostic value than transplant eligibility and the Revised International Staging System (R-ISS). Multiomics analyses of patient samples and mouse models revealed genomic evolution, transcriptional adaptation, and changes in the tumor-immune microenvironment associated with MRD resistance; additionally, anti-BCMA CAR T-cell treatment at persistent MRD prolonged survival compared with treatment at relapse in MIcγ1hCRBN mouse models.
Key points
MRD dynamics and patient stratification
• MRD dynamics were evaluated in 539 patients with newly diagnosed MM enrolled in the GEM2012MENOS65/GEM2014MAIN and GEM2017FIT clinical trials.
• A total of 3,610 MRD assessments were analyzed using next-generation flow cytometry (NGF) and CONNECTOR, a data-driven framework for analyzing longitudinal data.
• Five patient subgroups with distinct survival outcomes were identified:
- Early sustained MRD response
- Late sustained MRD response
- Volatile MRD results
- Primarily MRD resistance
- Resurgent MRD resistance
• Patients with late sustained MRD response had excellent outcomes, similar to those with early sustained MRD response.
• Patients with volatile MRD results, primarily MRD resistance, and resurgent MRD resistance had poorer survival outcomes.
• MRD dynamics demonstrated stronger prognostic value than transplant eligibility and R-ISS.
Validation in routine clinical practice
• The findings were independently validated in 249 patients with MM treated with standard-of-care regimens at the National and Kapodistrian University of Athens Alexandra General Hospital.
• Median follow-up was:
- 6.4 years in the clinical trial cohort
- 4.1 years in the real-world validation cohort
• Patients with early/sustained MRD response had survival rates exceeding 80% in clinical trials and 90% in the real-world setting.
Molecular and immune characteristics of MRD resistance
• Multiomics characterization included:
- Exome and RNA sequencing of MRD cells and paired diagnostic and relapsed tumor samples from 123 patients.
- Immune profiling of 225 paired bone marrow (BM) aspirates from 75 patients, collected at diagnosis, after induction, and after transplantation.
- Whole-genome sequencing and single-cell RNA and T-cell receptor sequencing in mouse models.
• MRD resistance was associated with:
- Genomic evolution
- Transcriptional adaptation
- Changes in the tumor-immune microenvironment
• No single unifying genetic alteration explained MRD resistance.
• Genomic divergence was greater in post-transplant MRD than in post-induction MRD.
• Immune profiling identified:
- Expansion of basophils, eosinophils, mast cells, and monocytes.
- Decreases in CD27+ and CD27− B cells and T-cell and natural killer (NK) cell subsets.
• Progressive exhaustion of endogenous clonal T cells was observed throughout disease progression.
Experimental MRD interception with anti-BCMA CAR T cells
• MIcγ1hCRBN mice received eight consecutive weeks of VRd treatment (bortezomib, lenalidomide, and dexamethasone).
• Mice with complete remission and persistent MRD were randomized into treatment groups:
- Anti-BCMA CAR T cells administered at persistent MRD (n = 16).
- Identical anti-BCMA CAR T-cell treatment administered at relapse (n = 9).
- Control mice received VRd without CAR T-cell therapy (n = 13).
• Anti-BCMA CAR T-cell administration at persistent MRD prolonged mouse survival compared with administration at relapse.
• The authors noted an important limitation of the experimental findings: overall survival was similar between untreated mice and mice receiving CAR T cells at relapse.
• The authors cautioned that the findings should not be generalized to patients because experimental mouse models do not fully reproduce human MM.
Study characteristics supporting the evaluation of the findings
• Inclusion of 539 patients with at least three MRD assessments in the clinical trial cohort
• Analysis of 3,610 longitudinal MRD assessments
• Independent validation in 249 patients treated in routine clinical practice
• Integration of genomic, transcriptomic, and immune profiling in patient samples and experimental models
• Investigation of treatment timing using human-like MM mouse models.
Limitations
• The use of exome sequencing instead of whole-genome sequencing, together with single-cell multiomics, resulted in an incomplete characterization of molecular mechanisms of MRD resistance, including mutational signatures.
• The study included limited use of quadruplet therapy, which is now the standard of care.
• The prognostic value of MRD dynamics requires further investigation in patients treated with T-cell–redirecting therapies.
• The experimental mouse models do not fully reproduce human MM. In particular, overall survival was similar between untreated mice and those receiving CAR T-cell therapy at relapse, limiting the generalizability of the experimental findings to patients.
Why this study matters
Serial MRD dynamics identified five patient subgroups with distinct survival outcomes and demonstrated stronger prognostic value than transplant eligibility and R-ISS in the studied clinical trial and real-world populations. Molecular and immune profiling identified genomic evolution, transcriptional adaptation, and tumor-immune microenvironment changes associated with MRD resistance, while anti-BCMA CAR T-cell treatment at persistent MRD prolonged survival compared with treatment at relapse in MIcγ1hCRBN mouse models. These findings support further investigation of serial MRD assessment and MRD interception in clinical trials; however, the survival benefit of early anti-BCMA CAR T-cell treatment in patients has not been established by this experimental comparison.
Reference:
Carmen Gonzalez, Camila Guerrero, Marta Larrayoz, Aintzane Zabaleta, Junfei Zhao, Ioannis V. Kostopoulos, Ourania E. Tsitsilonis, Evangelos Terpos, Norma C. Gutiérrez, Manuela Fernández, María-José Calasanz, Paula Rodriguez-Otero, Felipe Prosper, Teresa Lozano, Juan-José Lasarte, Benjamin L. Ebert, Albert Oriol, Anna Sureda, Maria-Jesus Blanchard, Yolanda Gonzalez, Joan Bargay, Sunil Lakhwani, Rafael Rios-Tamayo, Laura Rosiñol, Joaquin Martinez-Lopez, Juan-José Lahuerta, Joan Blade, Maria-Victoria Mateos, Jesús F. San Miguel, Maria-Teresa Cedena, Noemi Puig, Patrick Hagner, Maria Ortiz, José Angel Martinez-Climent, Bruno Paiva; MRD dynamics predicts progression and reveals a vulnerable state for immunotherapy interception in multiple myeloma. Blood 2026; 148 (19): 2368–2383. doi: https://doi.org/10.1182/blood.2026033878
Lower Dexamethasone Dose in Multiple Myeloma: A Multicenter Retrospective Analysis — Cancers (November 2026)
What is the purpose of the study?
To evaluate the association between different initial weekly dexamethasone doses (40 mg, 20 mg, or less than 20 mg) and clinical outcomes, including progression-free survival (PFS), treatment response, and adverse events, in patients with relapsed multiple myeloma receiving lenalidomide–dexamethasone (Rd) therapy. The study aims to assess the clinical outcomes associated with different dexamethasone dosing strategies in a real-world, multicenter setting.
Summary
This retrospective, multicenter study analyzed 272 patients with relapsed multiple myeloma who received lenalidomide–dexamethasone therapy at 11 Hungarian centers between 2010 and 2020, comparing outcomes among patients receiving initial weekly dexamethasone doses of 40 mg, 20 mg, or less than 20 mg. No statistically significant differences were observed among the three groups in progression-free survival (PFS; p = 0.632), overall response rate (ORR; p = 0.560), early treatment response at 2 and 6 months, or PFS among patients with high-risk cytogenetic abnormalities (p = 0.312). Grade 3–5 adverse events were numerically more frequent in the 40 mg group, although the overall distribution of adverse event grades did not differ significantly between groups (p = 0.086).
Key points
Study design and patient characteristics
• Retrospective, multicenter study conducted across 11 Hungarian centers.
• Included 272 patients with relapsed multiple myeloma who received lenalidomide–dexamethasone (RD) as second- or later-line therapy between 2010 and 2020.
• Patients had received 1–4 previous lines of therapy.
• Patients were categorized according to their initial weekly dexamethasone dose: 40 mg (132 pts); 20 mg (100 pts); Less than 20 mg (40 pts); Total of 272 patients
• Older patients were more likely to receive lower dexamethasone doses.
• The primary endpoint was PFS. Secondary endpoints included overall response rate and early treatment response at 2 and 6 months.
• PFS was defined as the time from treatment initiation to disease progression or death.
Efficacy outcomes
• Progression-free survival (PFS): No statistically significant difference was observed among the three dexamethasone dose groups (p = 0.632).
• Overall response rate (ORR): No statistically significant association was found between dexamethasone dose intensity and overall treatment response (p = 0.560). ORR was defined as the proportion of patients achieving complete response (CR), very good partial response (VGPR), or partial response (PR) as their best response.
• Early treatment response: Response rates at 2 and 6 months were not significantly associated with dexamethasone dose.
• High-risk cytogenetics: No statistically significant difference in PFS was observed among dose groups in the subgroup of patients with high-risk cytogenetic abnormalities (p = 0.312).
• Multivariate analysis: Dexamethasone dose intensity was not identified as an independent predictor of PFS.
Important statistical clarification
• The absence of statistically significant differences does not establish equivalent efficacy or demonstrate non-inferiority between the three dexamethasone dosing regimens.
Safety outcomes
• The overall distribution of adverse event grades did not differ significantly among the three groups (p = 0.086).
• Grade 3–5 adverse events were numerically more frequent in patients receiving 40 mg dexamethasone weekly: 40 mg (14.4%); 20 mg (6.0%); Less than 20 mg (2.5%)
• The numerical differences should not be interpreted as statistically significant differences in adverse event rates.
• Baseline differences between treatment groups and potential variability in adverse event reporting across centers limited the interpretation of these findings.
Methodological characteristics
• Multicenter design involving 11 Hungarian centers
• Real-world clinical data from 272 patients
• Comparison of three initial weekly dexamethasone dosing regimens
• Evaluation of both efficacy and safety outcomes
• Inclusion of subgroup analyses involving patients with high-risk cytogenetic abnormalities
• Use of univariate and multivariate statistical analyses.
Limitations
• Retrospective study design: Dexamethasone dosing was determined at the discretion of treating physicians rather than through randomized treatment allocation.
• Lack of objective frailty assessment: Standardized frailty scores were not systematically collected at treatment initiation.
• Potential confounding by indication: Patient characteristics influencing dexamethasone dose selection could not be fully accounted for.
• Incomplete clinical information: ECOG performance status and comorbidity data were not systematically available.
• Incomplete cytogenetic information: Cytogenetic data were missing for 93 patients (34.2%), limiting the interpretation and sample size of subgroup analyses.
• Unrecorded subsequent dose modifications: Dexamethasone dose reductions or discontinuations during treatment were not recorded and therefore could not be evaluated.
• Variability in adverse event reporting: Differences in baseline characteristics and potential variability in adverse event reporting across centers limited the interpretation of safety findings.
Why this study matters
In this retrospective multicenter study of 272 patients with relapsed multiple myeloma receiving lenalidomide–dexamethasone therapy, initial weekly dexamethasone doses of 20 mg or less than 20 mg were not associated with statistically significant differences in PFS, overall response rate, or early treatment response compared with the 40 mg dose group. Grade 3–5 adverse events were numerically more frequent in the 40 mg group, although the overall distribution of adverse event grades did not differ significantly. These findings do not establish equivalence or non-inferiority between dosing regimens, and prospective studies are needed to further evaluate the efficacy and safety of dexamethasone dose-reduction strategies.
Reference:
Korpás, L., Wiedemann, Á., Szél, F., Svorenj, S., Weisinger, J., Nagy, Z., Szemlaky, Z., Csukly, Z., Reményi, P., Rajnics, P., Altai, E., Plander, M., Kórád, K., Szaleczky, E., Masszi, A., Kosztolányi, S., Alizadeh, H., Modok, S., Borbényi, Z., ... Varga, G. (2026). Lower Dexamethasone Dose in Multiple Myeloma: A Multicenter Retrospective Analysis. Cancers, 18(21), 3565. https://doi.org/10.3390/cancers18213565
Influence of CAR T-cell expansion and persistence in the peripheral blood on CAR T-cell therapy efficacy and adverse events in multiple myeloma — Bone Marrow Transplantation (November 2026)
What is the purpose of the study?
To evaluate the clinical outcomes of patients with multiple myeloma (MM) treated with B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapies, ciltacabtagene autoleucel (cilta-cel) and idecabtagene vicleucel (ide-cel), and to investigate the association between CAR T-cell expansion in peripheral blood, treatment response, survival outcomes, and treatment-related adverse events, particularly neurotoxicity.
Summary
This retrospective study analyzed 40 patients with multiple myeloma treated with BCMA-directed CAR T-cell therapy (28 received cilta-cel and 12 received ide-cel) to assess CAR T-cell expansion, persistence, treatment response, survival, and adverse events. Patients with stronger CAR T-cell expansion generally achieved deeper responses (≥very good partial response [VGPR]) and had longer CAR T-cell persistence, while neurotoxicity, including immune effector cell-associated neurotoxicity syndrome (ICANS), was observed exclusively among strong expanders (26% vs. 0%; p = 0.02). However, strong CAR T-cell expansion was not significantly associated with progression-free survival (PFS) or overall survival (OS), and bone marrow infiltration of ≥50% was associated with significantly shorter PFS and OS.
Key points
Study population and treatment
• A total of 40 patients with multiple myeloma were included:
- Ciltacabtagene autoleucel (cilta-cel): 28 patients.
- Idecabtagene vicleucel (ide-cel): 12 patients.
• Patients were categorized according to CAR T-cell expansion:
- Poor expanders: 20 patients.
- Strong expanders: 19 patients.
- One patient was excluded because of insufficient CAR T-cell quantification data.
• Expansion was measured in peripheral blood using flow cytometry and classified using therapy-specific thresholds:
- Cilta-cel: poor expansion less than 58 cells/µL; strong expansion ≥58 cells/µL.
- Ide-cel: poor expansion less than 19 cells/µL; strong expansion ≥19 cells/µL.
CAR T-cell expansion and treatment response
• Patients achieving ≥VGPR demonstrated higher CAR T-cell expansion and longer persistence.
• Median peak CAR T-cell levels among patients achieving ≥VGPR were 272 cells/µL, with a range of 5–17,780 cells/µL, within 15 days after infusion.
• Patients with poor responses had consistently lower CAR T-cell levels over time.
• None of the poor responders had detectable CAR T cells beyond day 200.
• Two poor responders had no detectable CAR T-cell expansion at any measured time point and subsequently experienced disease progression and died during follow-up.
• CAR T-cell persistence in peripheral blood was longer with cilta-cel than ide-cel:
- Cilta-cel: median 70 days (range, 0–308).
- Ide-cel: median 40 days (range, 0–204).
• Strong CAR T-cell expansion was not significantly associated with PFS or OS.
Factors associated with CAR T-cell expansion
• Pre-treatment lymphopenia was more frequent among poor expanders:
- Before apheresis: severe lymphopenia in 40% of poor expanders versus 16% of strong expanders (p = 0.16).
- Before infusion: 50% versus 26%, respectively (p = 0.23).
• These differences were not statistically significant.
• No significant differences in CRP, ferritin, or CAR-HEMATOTOX (HT) scores were observed between expansion groups.
• Prior ASCT and the number of previous treatment lines were not significantly associated with CAR T-cell expansion.
• Bone marrow infiltration ≥50% was significantly associated with:
- Lower PFS (p less than 0.0001)
- Lower OS (p = 0.02)
Safety and treatment-related adverse events
• Cytokine release syndrome (CRS) occurred in 82.5% of the overall cohort; all cases were grade 1 or 2.
• Immune effector cell-associated neurotoxicity syndrome (ICANS) occurred in 4 patients (10%):
- All cases occurred in the cilta-cel group.
- Two patients had grade 1 and two had grade 2 ICANS.
• Delayed neurotoxicity (DNT) occurred in 1 patient receiving cilta-cel (1/28; 3.6%), presenting as unilateral facial nerve palsy on day 22 after infusion. The condition resolved following corticosteroid treatment.
• Neurotoxicity was observed exclusively among strong expanders:
- Any neurotoxicity: 26% versus 0% in poor expanders (p = 0.02).
- ICANS: 21% versus 0% (p = 0.05).
• CRS incidence was comparable between poor and strong expanders:
- Any-grade CRS: 80% versus 84% (p = 1.00).
- Grade ≥2 CRS: 50% versus 53% (p = 1.00).
• The incidence of significant leukopenia, neutropenia, and thrombocytopenia was comparable between cilta-cel and ide-cel recipients.
• Two secondary malignancies were reported: therapy-related acute myeloid leukemia (t-AML) and cutaneous squamous cell carcinoma.
Limitations
• Small sample size, limiting statistical power, and increasing the influence of individual cases.
• Heterogeneous patient population with different pretreatment histories and baseline characteristics, reducing comparability.
• Variable follow-up durations, affecting the consistency of PFS and OS assessments.
• Retrospective study design, which may introduce bias and limit the generalizability of the findings.
Why this study matters
In this retrospective cohort of 40 patients with multiple myeloma, greater BCMA CAR T-cell expansion was associated with deeper treatment responses and increased neurotoxicity, particularly ICANS, but was not significantly associated with PFS or OS. Cilta-cel demonstrated longer CAR T-cell persistence than ide-cel, while bone marrow infiltration ≥50% was significantly associated with poorer PFS and OS. Larger studies are needed to further evaluate these associations and determine the clinical relevance of CAR T-cell expansion in predicting treatment response and neurotoxicity.
Reference:
Boettger, M., Sauerborn, P., Ihorst, G. et al. Influence of CAR T-cell expansion and persistence in the peripheral blood on CAR T-cell therapy efficacy and adverse events in multiple myeloma. Bone Marrow Transplant (2026). https://doi.org/10.1038/s41409-026-03083-w
Clinical Trials
Final analysis results from DREAMM-3, a phase 3 study of belantamab mafodotin versus pomalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma — Blood Cancer Journal (October 2026)
What is the purpose of the study?
To evaluate the long-term efficacy and safety of belantamab mafodotin monotherapy compared with pomalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM) in the final analysis of the phase 3 DREAMM-3 trial (NCT04162210). The analysis assesses progression-free survival (PFS), overall survival (OS), treatment response, and adverse events during extended follow-up.
Summary
DREAMM-3 was a multicenter, open-label, randomized phase 3 trial involving 325 patients with RRMM who had received at least two prior lines of therapy, including lenalidomide and a proteasome inhibitor. Patients were randomized 2:1 to receive belantamab mafodotin monotherapy (n = 218) or pomalidomide-dexamethasone (n = 107). At the final analysis (data cutoff: April 22, 2025), median PFS was 11.2 months versus 7.0 months (hazard ratio [HR], 0.87; 95% confidence interval [CI], 0.64–1.18), and median OS was 24.0 months versus 22.9 months (HR, 0.98; 95% CI, 0.73–1.30), respectively. The primary PFS superiority endpoint was not met at the initial analysis (HR, 1.03; 95% CI, 0.72–1.47; p = 0.56), and the final analysis was descriptive, with no prespecified formal hypothesis testing; therefore, the final PFS results are descriptive estimates rather than confirmatory evidence of superiority. No new safety signals were identified during long-term follow-up, although ocular adverse events were more frequent with belantamab mafodotin.
Key points
• Study design: Multicenter, open-label, randomized phase 3 trial, DREAMM-3 (NCT04162210)
• Participants: 325 patients with RRMM who had received at least two prior lines of therapy, including lenalidomide and a proteasome inhibitor.
• Treatment allocation: Belantamab mafodotin monotherapy (n = 218) versus pomalidomide-dexamethasone (n = 107), in a 2:1 ratio
• Follow-up: Median follow-up was 22.2 months (interquartile range [IQR], 7.0–45.7) with belantamab mafodotin and 21.9 months (IQR, 8.4–42.8) with pomalidomide-dexamethasone.
• Progression-free survival (PFS):
- Median PFS was 11.2 months (95% CI, 6.5–14.5) with belantamab mafodotin and 7.0 months (95% CI, 4.6–10.6) with pomalidomide-dexamethasone.
- The final-analysis HR was 0.87 (95% CI, 0.64–1.18).
- The primary PFS superiority endpoint was not met at the initial analysis: HR, 1.03 (95% CI, 0.72–1.47; p = 0.56). The post-primary and final PFS HRs were 0.90 (95% CI, 0.65–1.24) and 0.87 (95% CI, 0.64–1.18), respectively.
- The final analysis was descriptive, with no prespecified formal hypothesis testing. Therefore, the final PFS results should be interpreted as descriptive estimates rather than confirmatory evidence of superiority.
Other efficacy outcomes
• Stringent complete response rates were 9% and 3%, respectively.
• Complete response or better with minimal residual disease (MRD) negativity at the 10−5 threshold was observed in 8% and less than 1%, respectively.
• Median PFS2, defined as time from randomization to progression on a subsequent line of therapy, was 17.3 months (95% CI, 13.8–21.7) and 13.0 months (95% CI, 10.6–15.5), respectively.
Safety outcomes
• Grade 3–4 adverse events occurred in 71% of patients receiving belantamab mafodotin and 66% receiving pomalidomide-dexamethasone.
• Blurred vision occurred in 48% and 7%, respectively.
• Thrombocytopenia occurred in 35% versus 34%, anemia in 29% versus 34%, and neutropenia in 12% versus 40%, respectively.
• Increases in aspartate aminotransferase occurred in 17% versus 6%, gamma-glutamyltransferase in 14% versus 6%, and alanine aminotransferase in 9% versus 10%; abnormal liver function was reported in 6% versus 0%, respectively.
• Exposure-adjusted infection/infestation incidence rates were 51.8 per 100 person-years (15.6 Grade 3 or higher) with belantamab mafodotin and 62.8 per 100 person-years (38.8 Grade 3 or higher) with pomalidomide-dexamethasone.
• Among 122 patients with a first Grade 2 or higher ophthalmic examination finding, 98 (80%) recovered to Grade 1 or better by the data cutoff. Twenty-four patients had unresolved Grade 2 or higher findings on their last visit.
• Ocular events were managed with dose delays and reductions. No new safety signals were identified during long-term follow-up.
Study design considerations discussed by the authors
• The primary PFS superiority endpoint was not met.
• The authors stated that a non-inferiority hypothesis might have been more appropriate than the superiority hypothesis used in DREAMM-3.
• They also noted that longer follow-up before the primary analysis might have provided more opportunity to observe separation in efficacy endpoints, while acknowledging that non-proportional hazards would remain.
Why this study matters
In the final descriptive analysis of DREAMM-3, median PFS was 11.2 months with belantamab mafodotin monotherapy and 7.0 months with pomalidomide-dexamethasone, while median OS was 24.0 and 22.9 months, respectively. The trial did not meet its primary PFS superiority endpoint, and the final analysis included no prespecified formal hypothesis testing; therefore, the final PFS results are descriptive estimates rather than confirmatory evidence of superiority. Long-term follow-up identified no new safety signals, although ocular adverse events were more frequent with belantamab mafodotin and were managed through dose delays and reductions.
Reference:
Dimopoulos, M.A., Hungria, V., Meng, H. et al. Final analysis results from DREAMM-3, a phase 3 study of belantamab mafodotin versus pomalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma. Blood Cancer J. 16, 184 (2026). https://doi.org/10.1038/s41408-026-01646-0
Molecular predictors of minimal residual disease in newly diagnosed multiple myeloma treated with quadruplet therapy — Nature Medicine (October 2026)
What is the purpose of the study?
To characterize the genomic, transcriptomic, and epigenomic heterogeneity of newly diagnosed multiple myeloma (NDMM) and identify molecular features associated with measurable residual disease (MRD) status after induction therapy with isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd). It also aims to evaluate whether integrating these molecular features could improve the prediction of postinduction MRD status.
Summary
This ancillary study of the phase 3 MIDAS trial (ClinicalTrials.gov identifier: NCT04934475) integrated genomic, transcriptomic, and DNA methylation profiling of 423 tumor samples from patients with NDMM treated with Isa-KRd. Postinduction MRD-negativity rates varied significantly across gene expression subtypes, with HP1/HP3 and MS groups showing superior responses compared with the MF and CD2 subtypes; B cell differentiation was associated with MRD positivity, whereas proliferation and MYC-related programs were associated with MRD negativity, with the transcriptomic associations independently validated in the CASSIOPEIA cohort. A multimodal random forest model integrating genomic, transcriptomic, and epigenomic features predicted postinduction MRD status with an area under the receiver operating characteristic curve (AUC) of 0.77, outperforming clinical and genomic models while providing discrimination comparable to, and improved calibration relative to, transcriptomic and epigenomic models.
Key points
• Study design and population: Integrated multiomic analysis of 423 tumor samples from patients with NDMM enrolled in the MIDAS cohort, who received uniform induction therapy with Isa-KRd.
• Differences in treatment response: Postinduction MRD-negativity rates varied significantly across gene expression subtypes. HP1/HP3 and MS showed superior responses compared with MF and CD2. These findings describe differences between subtypes and do not establish that every pairwise comparison was statistically significant.
• Transcriptomic associations: B cell differentiation was associated with MRD positivity, whereas proliferation and MYC-related programs were associated with MRD negativity. These MRD-associated transcriptomic features were independently validated in the CASSIOPEIA cohort.
• Genomic findings: Whole-genome sequencing identified established genomic instability processes, including APOBEC-mediated mutagenesis and chromothripsis, as well as newly characterized genomic instability phenotypes. New driver alterations were independently validated across three external multiple myeloma cohorts: MMRF, MANHATTAN, and CASSIOPEIA, comprising 1,451 cases.
• Genomic features associated with MRD: Genomic instability features and driver genes, including CCND1 and MYC, were associated with differential MRD outcomes.
• Epigenomic findings: DNA methylation profiling identified nine MRD-associated subgroups distinguished by the extent of hypomethylation in quiescent chromatin and by cis-acting and trans-acting signatures of driver translocations.
• Predictive model performance: A multimodal random forest model integrating genomic, transcriptomic, and epigenomic features achieved an AUC of 0.77 for predicting postinduction MRD status. It outperformed clinical and genomic models. Its discrimination was comparable to that of the transcriptomic and epigenomic models, while its calibration was improved relative to those models.
Strengths
• A large, prospectively collected cohort of newly diagnosed patients treated uniformly within a clinical trial.
• Integrated genomic, transcriptomic, and epigenomic profiling to characterize molecular heterogeneity.
• External validation of findings across independent multiple myeloma cohorts.
• The identification of rare molecular subgroups and infrequent driver alterations beyond those captured by established classification systems.
Limitations
• The limited number of cases with rare DNA repair deficiencies, including MSH2 alterations, restricts conclusions about their potential clinical or therapeutic relevance. Validation in larger datasets and functional studies is needed.
• Consolidation therapy was administered between the postinduction and premaintenance MRD assessments, complicating the interpretation of changes in MRD status and the contribution of treatment effects versus intrinsic response kinetics.
• Whether early differences in MRD status translate into differences in sustained MRD, progression-free survival, or overall survival remains to be determined through further MIDAS follow-up.
Why this study matters
Integrated genomic, transcriptomic, and epigenomic profiling identified molecular subgroups and features associated with MRD status after Isa-KRd induction in patients with NDMM. The multimodal random forest model predicted postinduction MRD status with an AUC of 0.77, outperforming clinical and genomic models while showing discrimination comparable to, and improved calibration relative to, transcriptomic and epigenomic models. Further follow-up is required to determine whether these molecular associations and early MRD differences are related to sustained MRD status, progression-free survival, and overall survival.
Reference:
Magrangeas, F., Cherkaoui, M., Bessonneau-Gaborit, V. et al. Molecular predictors of minimal residual disease in newly diagnosed multiple myeloma treated with quadruplet therapy. Nat Med (2026). https://doi.org/10.1038/s41591-026-04692-0
Elrexfio (Elranatamab) meets primary endpoint in Phase 3 MagnetisMM-32 trial vs standard regimens in relapsed/refractory myeloma — Pfizer (October 2026)
What is the purpose of the study?
The Phase 3 MagnetisMM-32 study evaluates the efficacy and safety of ELREXFIO (elranatamab) monotherapy compared with investigator’s choice of three standard treatment regimens in adults with relapsed or refractory multiple myeloma (RRMM) who had received at least one prior line of treatment with anti-CD38 therapy and lenalidomide. The primary objective is to assess progression-free survival (PFS), with overall survival (OS) as a key secondary endpoint.
Summary
In the randomized, open-label, multicenter Phase 3 MagnetisMM-32 trial involving 523 adults across 26 countries, Elrexfio (elranatamab) met its primary endpoint at the prespecified interim efficacy analysis, demonstrating a statistically significant and clinically meaningful reduction in the risk of disease progression or death compared with investigator’s choice of elotuzumab, pomalidomide, and dexamethasone (EloPd); pomalidomide, bortezomib, and dexamethasone (PVd); or carfilzomib and dexamethasone (Kd), as assessed by blinded independent central review (BICR). Median PFS had not been reached, and the estimated PFS rate at 18 months was 68%; OS data remained immature, and the safety profile was consistent with the known profile of Elrexfio (elranatamab), with no new safety signals identified.
Key points
• Study design: Randomized, open-label, multicenter Phase 3 clinical trial.
• Study population: 523 adults with RRMM across 26 countries who had received at least one prior line of treatment with anti-CD38 therapy (daratumumab or isatuximab) and lenalidomide.
• Intervention: Subcutaneous ELREXFIO (elranatamab) monotherapy, administered using two step-up priming doses followed by weekly dosing, with subsequent transition to every-two-week and monthly dosing.
• Comparator: Investigator’s choice of one of three established regimens:
- EloPd: elotuzumab, pomalidomide, and dexamethasone
- PVd: pomalidomide, bortezomib, and dexamethasone
- Kd: carfilzomib and dexamethasone
• Primary endpoint: Progression-free survival (PFS), assessed by BICR
• Key secondary endpoint: Overall survival (OS)
• Primary endpoint result: The study met its primary endpoint at the prespecified interim efficacy analysis, showing a statistically significant and clinically meaningful reduction in the risk of disease progression or death with ELREXFIO versus investigator’s choice.
• PFS findings: Median PFS had not been reached at the time of analysis. More than 75% of patients receiving ELREXFIO had not experienced disease progression or death, and the estimated PFS rate at 18 months was 68%.
• OS findings: OS data were immature, with follow-up continuing until the next prespecified OS analysis.
• Safety findings: The safety profile was consistent with the known profile of ELREXFIO, and no new safety signals were identified. Grade 3 or higher infections occurred in 27.5% of patients receiving ELREXFIO versus 18.1% receiving investigator’s choice; Grade 5 infections occurred in 0.8% versus 1.6%, respectively.
• Infection prevention: Infection prophylaxis measures were implemented from the beginning of the study to help mitigate infection risk, including Grade 3 or higher infections.
• Next steps: Pfizer plans to submit the data to global health authorities and share detailed results at a future medical meeting and in a publication.
Strengths
The randomized Phase 3 design, assessment of PFS by blinded independent central review, and comparison against investigator’s choice of three established standard-of-care regimens.
Limitations
OS data were immature at the interim analysis, and follow-up was ongoing. Detailed results had not yet been reported in a medical meeting or publication at the time of the announcement.
Why this study matters
The Phase 3 MagnetisMM-32 trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful reduction in the risk of disease progression or death with ELREXFIO compared with investigator’s choice of EloPd, PVd, or Kd in adults with RRMM previously treated with anti-CD38 therapy and lenalidomide. Median PFS had not been reached, and the estimated 18-month PFS rate was 68%; the safety profile was consistent with previous knowledge of ELREXFIO, although Grade 3 or higher infections occurred in 27.5% of ELREXFIO-treated patients versus 18.1% of patients receiving investigator’s choice. Overall survival data remain immature, and further follow-up is ongoing.
Reference:
Pfizer’s ELREXFIO Outperforms Standard Regimens and Meets Primary Endpoint in Phase 3 Study in Relapsed or Refractory Multiple Myeloma. Pfizer press release. October 27, 2026.
Phase 1/2 trial of Evomela for autologous transplant in myeloma: schedule optimization and matched comparison with MEL200 — Blood Advances (November 2026)
What is the purpose of the study?
To evaluate and optimize the dose and infusion schedule of Evomela (propylene glycol–free melphalan) as a conditioning regimen for autologous hematopoietic stem cell transplantation (ASCT) in patients with newly diagnosed multiple myeloma (MM). The study also aims to characterize the pharmacokinetics (PK) of melphalan and assess the relationship between systemic drug exposure, treatment response, toxicity, and progression-free survival (PFS).
Summary
This prospective, single-center, randomized phase 1/2 trial (NCT03417284) enrolled 60 patients with newly diagnosed MM undergoing ASCT. Patients received Evomela at 200 or 225 mg/m² through either a short (30–60 minutes) or long (8–9 hours) infusion, with dose selection guided by a Bayesian dose-finding model. The day-90 minimal residual disease (MRD)-negative stringent complete response (sCR)/complete response (CR) rate was 45%, with no significant difference between infusion schedules; higher melphalan area under the concentration–time curve (AUC) was strongly associated with MRD-negative sCR/CR (posterior probability of benefit [PBE] = 0.99), without a significant association with increased toxicity or PFS. In a separate propensity-score-matched, nonrandomized comparison with conventional melphalan 200 mg/m² (MEL200), Evomela was associated with a higher day-90 MRD-negative sCR/CR rate (45% vs 30%) and a 90% posterior probability of reduced risk of progression or death. These comparative findings are hypothesis-generating and do not establish a definitive survival benefit.
Key points
Study design and treatment
• Prospective, investigator-initiated, single-center, randomized phase 1/2 clinical trial
• Clinical trial registration: NCT03417284
• Participants: 60 transplant-eligible patients aged 18–70 years with newly diagnosed MM who had achieved partial response or better following induction therapy.
• Patients were randomized 1:1 to receive Evomela on day −2 through either:
- Short infusion: 30–60 minutes.
- Long infusion: 8–9 hours.
•Two Evomela doses were evaluated: 200 and 225 mg/m². Dose selection within the infusion schedules was guided by a Bayesian model-averaging continual reassessment method.
• Autologous stem cells were infused on day 0.
• Primary objectives included dose and infusion-schedule optimization and PK characterization. Secondary objectives included day-90 MRD-negative sCR/CR, toxicity, and PFS.
Efficacy and treatment response
• Overall response rate at day 90 after ASCT was 98% (59/60).
• Overall sCR/CR rate at day 90 was 50% (30/60).
• MRD-negative sCR/CR rates among all Evomela-treated patients were:
- Day 90: 45% (27/60)
- One year: 62% (37/60)
• Day-90 MRD-negative sCR/CR rates by infusion schedule:
- Short infusion: 43% (13/30)
- Long infusion: 47% (14/30)
• No significant difference was identified between infusion schedules in the probability of achieving day-90 MRD-negative sCR/CR (PBE = 0.31).
• In the propensity-score-matched comparison with MEL200:
- Evomela: 45% MRD-negative sCR/CR
- MEL200: 30% MRD-negative sCR/CR
- The posterior probability favoring Evomela for achieving MRD-negative sCR/CR was 0.84
Pharmacokinetics (PK) and exposure-response relationship
• Higher melphalan AUC was strongly associated with an increased probability of achieving day-90 MRD-negative sCR/CR (PBE = 0.99).
• Higher peak plasma concentration (Cmax) was not associated with an increased probability of achieving MRD-negative sCR/CR.
• Median melphalan AUC was 17,822 ng·h/mL overall
• Median Cmax differed between infusion schedules:
- Short infusion: 11,484 ng/mL
- Long infusion: 2,587 ng/mL
• Receiver operating characteristic (ROC) analysis identified an approximate AUC cutoff of 17,800 ng·h/mL, with moderate discriminatory ability (ROC AUC ≈ 0.65).
• Among patients with an AUC below 17,800 ng·h/mL, the day-90 MRD-negative sCR/CR rate was 26% (7/27).
• Among patients with an AUC of at least 17,800 ng·h/mL, the corresponding rate was 59% (17/29).
• No significant association was identified between PK parameters and PFS.
• The approximate AUC cutoff represents an exploratory exposure-response threshold and was not established as a definitive therapeutic target.
Safety and adverse events
• No grade ≥4 adverse events were observed.
• No grade ≥4 nonhematologic toxicities occurred.
• Grade ≥3 nonhematologic adverse events occurred in 67% (40/60) of patients:
- Short-infusion arm: 57% (17/30)
- Long-infusion arm: 77% (23/30)
• The most common grade 2/3 adverse event was nausea:
- Short-infusion arm: 63% (19/30)
- Long-infusion arm: 80% (24/30)
• Grade ≥2 mucositis/esophagitis occurred in:
- Short-infusion arm: 17% (5/30)
- Long-infusion arm: 30% (9/30).
• Atrial fibrillation was reported in two patients, one in each infusion arm.
• Both 100-day and one-year nonrelapse mortality (NRM) were 0%.
• No significant association was identified between systemic melphalan exposure (AUC or Cmax) and the incidence of grade ≥2 nausea, diarrhea, esophagitis, or other grade ≥3 nonhematologic adverse events.
Progression-free survival
• At a median follow-up of 35.5 months among surviving patients, median PFS was:
- Not reached in the short-infusion arm
- 58 months in the long-infusion arm
• No statistically meaningful PFS difference was identified between the two Evomela infusion schedules (P = 0.488).
• No significant association was identified between melphalan AUC and PFS.
• In the propensity-score-matched comparison with MEL200, Evomela had a 90% posterior probability of reduced risk of progression or death (PBE = 0.90).
• This comparison was nonrandomized and based on historical controls. Therefore, the result represents a posterior probability from an adjusted observational comparison, not definitive evidence of a causal PFS benefit or a quantified reduction in progression or death.
Methodological features
• Prospective randomized phase 1/2 design for evaluating Evomela dose and infusion schedules.
• Bayesian dose-finding approach to guide dose optimization.
• PK assessment using measured plasma melphalan concentrations and noncompartmental analysis.
• MRD assessment using an 8-color next-generation flow cytometry (NGF) assay validated to a sensitivity of 10⁻⁵ (0.001%).
• Propensity-score matching and Bayesian regression models were used for the separate comparison with a contemporary MEL200 control cohort.
Study limitations
• Single-center design: May limit the generalizability of the findings.
• Small sample size: Limits the reliability of subgroup analyses, particularly among patients with high-risk cytogenetics.
• Imbalance in high-risk cytogenetics: High-risk cytogenetics were present in 20% of patients in the long-infusion arm versus 10% in the short-infusion arm, potentially introducing residual confounding.
• Heterogeneous maintenance therapy: Post-ASCT maintenance treatment was not standardized, potentially confounding the assessment of PFS.
• Limited follow-up: The relatively short PFS follow-up period does not allow definitive conclusions about survival outcomes.
• Nonrandomized historical control comparison: Despite propensity-score matching, the Evomela-versus-MEL200 comparison remains susceptible to unmeasured confounding.
• Differences in induction therapy: Only 20% of participants received quadruplet induction therapy, which limits direct comparison with populations receiving contemporary quadruplet regimens.
Why this study matters
In this prospective randomized phase 1/2 trial, Evomela at doses of 200 and 225 mg/m² was associated with a 45% day-90 MRD-negative sCR/CR rate, with no observed grade ≥4 adverse events or 100-day NRM. Higher melphalan AUC was strongly associated with deeper MRD-negative responses, whereas infusion schedule was not associated with significant differences in response or PFS. In a separate propensity-score-matched, nonrandomized comparison, Evomela was associated with higher MRD-negative sCR/CR rates and a 90% posterior probability of reduced risk of progression or death compared with MEL200; however, these findings are not confirmatory evidence of a causal survival benefit and require evaluation in prospective randomized studies.
Reference:
Qaiser Bashir, Peter F. Thall, Jitesh D. Kawedia, Xun Xu, Cristina G. Knape, Ruby Delgado, Yago Nieto, Neeraj Saini, Yosra M. Aljawai, Samer A. Srour, Jeremy L. Ramdial, Chitra Hosing, Uday R. Popat, Betul Oran, Partow Kebriaei, Sairah Ahmed, Oren Pasvolsky, Krina Patel, Sheeba Thomas, Mahmoud Gaballa, Christine Ye, Robert Z. Orlowski, Richard E. Champlin, Elizabeth J. Shpall, Muzaffar H. Qazilbash; Phase 1/2 trial of Evomela for autologous transplant in myeloma: schedule optimization and matched comparison with MEL200. Blood Adv 2026; 10 (21): 7218–7229. doi: https://doi.org/10.1182/bloodadvances.2026020293
U.S. Food and Drug Administration (FDA)
Biologics License Application (BLA) submitted to U.S. FDA for etentamig (ABBV-383), as therapy for relapsed/refractory myeloma
On Tuesday, October 27, AbbVie announced via press release that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for etentamig (ABBV-383), an investigational, second-generation B-cell maturation antigen (BCMA)–directed CD3 bispecific antibody T-cell engager. Intravenous therapy is being developed for adults with relapsed or refractory multiple myeloma (RRMM).
The application is supported by results from the Phase 3 CERVINO study (NCT06158841), which evaluated etentamig against investigator-selected standard available therapies (SAT) in patients whose disease had been exposed to a proteasome inhibitor, an immunomodulatory drug and an anti-CD38 monoclonal antibody, and who had received at least two prior lines of treatment.
In the randomized, open-label CERVINO trial, 393 patients were assigned in a 1:1 ratio to receive etentamig or one of three standard treatment regimens: carfilzomib plus dexamethasone; elotuzumab plus pomalidomide and dexamethasone; or selinexor plus bortezomib and dexamethasone.
Etentamig met both primary endpoints, demonstrating statistically significant improvements in overall response rate (ORR) and progression-free survival (PFS) compared with SAT.
- Overall response rate: 74.0% with etentamig versus 45.7% with SAT.
- Progression-free survival: Etentamig reduced the risk of disease progression or death by 60% compared with SAT.
Abbvie did not provide median PFS values or the corresponding confidence intervals in the announcement. The reported relative risk reduction therefore should not be interpreted as a 60-percentage-point improvement in the proportion of patients who remain progression-free.
Key secondary endpoints include overall survival, depth of response, measurable residual disease (MRD) negativity, disease symptoms and physical functioning.
Safety findings
The most common treatment-emergent adverse events (TEAEs), reported in at least 25% of patients receiving etentamig, included cytokine release syndrome (CRS), hypogammaglobulinemia, neutropenia and anemia.
The company reported the following safety findings:
- Cytokine release syndrome: Among patients who received the single step-up dose, 28.3% experienced CRS. All reported cases were grade 1 (23.9%) or grade 2 (4.4%); no grade 3 or higher cases were reported in this group.
- Neurotoxicity: One patient experienced a grade 1 immune effector cell-associated neurotoxicity syndrome (ICANS) event.
- Serious infections by severity: Grade 3 or 4 infections occurred in 27.7% of patients receiving etentamig, compared with 19.2% receiving SAT. Grade 5 infections occurred in 1.5% and 3.1%, respectively.
- Treatment discontinuation: Adverse event-related discontinuations were reported in 3.6% of patients receiving etentamig versus 14% receiving SAT.
Etentamig was administered using a dosing strategy consisting of one step-up dose followed by dosing every four weeks (Q4W) from treatment initiation. AbbVie said this schedule and the observed safety findings may distinguish the therapy from other treatment approaches. However, the higher rate of grade 3 or 4 infections in the etentamig group remains an important consideration when assessing its overall safety profile.
Mechanism and dosing approach
Etentamig is designed to bind BCMA on malignant plasma cells and CD3 on T cells, bringing the immune cells into proximity with myeloma cells to promote their destruction.
Its structure includes a low-affinity CD3-binding domain, a high-affinity bivalent BCMA-binding domain and retained neonatal Fc receptor (FcRn) binding, which supports the proposed monthly dosing schedule after a single step-up dose. The company has proposed that these features may help reduce CRS and infections while maintaining antimyeloma activity. The direct relationship between the drug's structural features and its clinical effects remains under investigation.
According to AbbVie, the proposed monthly dosing schedule may offer greater flexibility in treatment delivery, including in community-based care settings. Whether etentamig can be administered broadly in these settings will depend on its eventual FDA-approved labeling, safety requirements and clinical practice considerations.
Next steps
Etentamig remains investigational, and the FDA's review will determine whether it can be approved for the proposed indication. The submission does not establish that the drug is approved or commercially available for this use.
AbbVie is also evaluating etentamig in other clinical studies and treatment settings. Further information about its ongoing trials is available through ClinicalTrials.gov.
Reference:
AbbVie Submits Biologics License Application (BLA) for Etentamig to U.S. FDA for Adults Living with Relapsed/Refractory Multiple Myeloma. Abbvie Press Release. October 27, 2026.
European Commission (EC)
European Commission expands marketing authorization for Pepaxti (melphalan flufenamide/melflufen) as third-line treatment for relapsed/refractory myeloma
On Monday, November 9, the European Commission (EC) approved a Type II variation application expanding the marketing authorization for Pepaxti (melphalan flufenamide/melflufen), allowing its use in adults with relapsed or refractory multiple myeloma (RRMM) from the third line of treatment, following at least two prior lines of therapy, states Oncopeptides in a press release.
The expanded indication applies to patients whose disease is refractory to lenalidomide and their last line of therapy. For patients who have previously undergone autologous stem cell transplantation (ASCT), disease progression must occur at least three years after transplantation.
The decision formally confirms the positive opinion issued by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP). It expands Pepaxti's previous indication from fourth-line treatment to third line and later treatment, removing the requirement for triple-class refractoriness (TCR).
According to Oncopeptides AB, the expanded indication could double the eligible patient population across Europe. Earlier treatment is also expected to extend treatment duration. Data from the Phase 3 OCEAN trial showed that patients receiving Pepaxti in the third-line setting received approximately twice the average number of treatment cycles compared with patients treated in the fourth-line setting.
The expanded indication is supported by efficacy data from the Phase 3 OCEAN trial and safety data from multiple clinical trials and real-world evidence evaluating Pepaxti in combination with dexamethasone in patients with RRMM.
Oncopeptides CEO Sofia Heigis said the approval would allow physicians to prescribe Pepaxti earlier in the treatment pathway, making more patients eligible for treatment. She also said the expanded indication and longer treatment duration could strengthen the company's commercial prospects and support its ambition to achieve positive cash flow during 2027.
Commercial rollout across Europe
Oncopeptides plans to submit its market access dossier in Germany within approximately one month. According to the company, the submission would allow commercial sales in the third-line setting while the health benefit assessment and subsequent pricing negotiations are underway.
In Germany, a pricing approach based on a basket averaging modern third-line therapies is already being used. Oncopeptides intends to use this framework as a comparative price reference to support Pepaxti's positioning.
The company also plans to pursue pricing and reimbursement procedures in other key European markets, including Spain and Italy, according to local submission timelines. It is also evaluating opportunities to introduce the expanded indication in additional markets.
Oncopeptides expects to leverage its existing commercial infrastructure to expand access across its key markets while limiting additional costs.
What is Pepaxti (melphalan flufenamide/melflufen)?
Pepaxti (melphalan flufenamide/ melflufen) is approved in the European Union, the European Economic Area countries Iceland, Liechtenstein and Norway, and the United Kingdom.
It is indicated in combination with dexamethasone for adults with multiple myeloma who have received at least two previous lines of therapy and whose disease is refractory to lenalidomide and their last line of treatment. For patients with a history of (ASCT), disease progression must occur at least three years after transplantation.
References:
European Commission approves label expansion of Pepaxti to third-line treatment. Oncopeptides press release. November 9, 2026.
Pepaxti (melphalan flufenamide or melflufen). European Medicines Agency.
For the latest, up-to-the-minute news on multiple myeloma, visit the IMF Newsroom.
The International Myeloma Foundation medical and editorial content team
Comprised of leading medical researchers, hematologists, oncologists, oncology-certified nurses, medical editors, and medical journalists, our team has extensive knowledge of the multiple myeloma treatment and care landscape.
Additionally, the content on this page is medically reviewed by myeloma physicians and healthcare professionals.
Medically reviewed on November 18, 2026.
This blog reflects medical guidance available at the time of review and is not routinely updated.




